var title_f42_3_43056="Hummingbird sign in PSP";
var content_f42_3_43056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    \"Penguin\" or \"hummingbird\" sign and midbrain atrophy in progressive supranuclear palsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Midsagittal MRI of the brain demonstrates prominent midbrain atrophy without pontine atrophy (divided by white line), forming the silhouette of the \"penguin\" or \"hummingbird\" sign.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Graber JJ, Staudinger R. Teaching NeuroImages: \"Penguin\" or \"hummingbird\" sign and midbrain atrophy in progressive supranuclear palsy. Neurology 2009; 72:e81. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43056=[""].join("\n");
var outline_f42_3_43056=null;
var title_f42_3_43057="Staple line dehiscence";
var content_f42_3_43057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Staple line dehiscence following gastric bypass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic appearance of a large staple line dehiscence, with easy access to the bypassed stomach (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher S Huang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43057=[""].join("\n");
var outline_f42_3_43057=null;
var title_f42_3_43058="Patient information: Osteoarthritis (The Basics)";
var content_f42_3_43058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15444\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/20/28993\">",
"         Osteoarthritis of the knee",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/63/35835\">",
"          Effects of osteoarthritis",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/3/11314\">",
"         Patient information: Gout (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/11/7347\">",
"         Patient information: Hand pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/59/12211\">",
"         Patient information: Paget disease of bone (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/31/16883\">",
"         Patient information: Rheumatoid arthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/62/28645\">",
"         Patient information: Arthritis and exercise (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/21/18769\">",
"         Patient information: Joint infection (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/46/16098\">",
"         Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/29/21975\">",
"         Patient information: Osteoarthritis treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/17/3345\">",
"         Patient information: Shoulder osteoarthritis treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/30/21987\">",
"         Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/13/21717\">",
"         Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Osteoarthritis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/osteoarthritis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H475075118\">",
"      <span class=\"h1\">",
"       What is osteoarthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Arthritis is a general term that means inflammation of the joints. There are dozens of types of arthritis. Osteoarthritis is the most common type. It often comes with age, and it often affects the hands, knees and hips.",
"     </p>",
"     <p>",
"      The place where two bones meet is normally covered with a rubbery material called cartilage. This material allows the bones to slide over each without causing pain. When osteoarthritis sets in, the cartilage begins to break down. As it wears away, the bones in the joint start to rub against each other (",
"      <a class=\"graphic graphic_figure graphicRef73149 \" href=\"mobipreview.htm?28/20/28993\">",
"       figure 1",
"      </a>",
"      ). This can cause pain, stiffness, and swelling (",
"      <a class=\"graphic graphic_table graphicRef77930 \" href=\"mobipreview.htm?34/63/35835\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H475075125\">",
"      <span class=\"h1\">",
"       What can I do to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To ease your symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Rest for several minutes when your pain is at its worst",
"        </strong>",
"        &ndash; But don&rsquo;t rest too long. That can make your muscles weak and your pain worse.",
"       </li>",
"       <li>",
"        <strong>",
"         Lose weight (if you are overweight)",
"        </strong>",
"        &ndash; Being heavy puts extra strain on your joints.",
"       </li>",
"       <li>",
"        <strong>",
"         Get some physical therapy and exercise",
"        </strong>",
"        &ndash; Having strong muscles takes some of the strain off of your joints. It can reduce your pain in the long run, even though it hurts to do at first.",
"       </li>",
"       <li>",
"        <strong>",
"         Use shoe inserts, splints, canes, walkers, or any other devices that help you",
"        </strong>",
"        &ndash; These devices can help keep your joints stable or take weight off them.",
"       </li>",
"       <li>",
"        <strong>",
"         Use hot or cold packs",
"        </strong>",
"       </li>",
"       <li>",
"        <strong>",
"         Learn about arthritis",
"        </strong>",
"        &ndash; That way you can work with your doctor or nurse to find the things that will help you.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H475075132\">",
"      <span class=\"h1\">",
"       Can herbs, vitamins, or supplements help?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no strong evidence that supplements of any sort work on arthritis symptoms. That&rsquo;s true even for glucosamine and chondroitin. Those are two supplements people seem to think help with arthritis. If you decide to try any supplements or herbs, check with your doctor or nurse before taking them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H475075139\">",
"      <span class=\"h1\">",
"       Are there medicines I can take?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are lots of medicines that can help you manage your osteoarthritis symptoms. Some simply reduce pain; others reduce swelling and pain. There are also creams and gels you can put on your skin to reduce pain. Plus, there are shots that go into the joint that can help with pain.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H475075146\">",
"      <span class=\"h1\">",
"       What about surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When other treatments do not help enough, some people with osteoarthritis get surgery. For instance, some people have surgery to replace a knee or a hip. Surgeons are working on other types of surgery for arthritis, too.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H475075153\">",
"      <span class=\"h1\">",
"       Try different things until you find what works",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of osteoarthritis can be hard to handle. But don&rsquo;t lose hope. You may need to try different combinations of medicines, exercises, and devices to find the approach that works for you. But most people do find ways to go back to doing many of things they like to do.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H475075202\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/31/16883?source=see_link\">",
"       Patient information: Rheumatoid arthritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/3/11314?source=see_link\">",
"       Patient information: Gout (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/11/7347?source=see_link\">",
"       Patient information: Hand pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/59/12211?source=see_link\">",
"       Patient information: Paget disease of bone (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28645?source=see_link\">",
"       Patient information: Arthritis and exercise (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/21/18769?source=see_link\">",
"       Patient information: Joint infection (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/46/16098?source=see_link\">",
"       Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/29/21975?source=see_link\">",
"       Patient information: Osteoarthritis treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/17/3345?source=see_link\">",
"       Patient information: Shoulder osteoarthritis treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/30/21987?source=see_link\">",
"       Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/13/21717?source=see_link\">",
"       Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/3/43058?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15444 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-EFBF5593C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43058=[""].join("\n");
var outline_f42_3_43058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H475075118\">",
"      What is osteoarthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H475075125\">",
"      What can I do to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H475075132\">",
"      Can herbs, vitamins, or supplements help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H475075139\">",
"      Are there medicines I can take?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H475075146\">",
"      What about surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H475075153\">",
"      Try different things until you find what works",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H475075202\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15444\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/20/28993\">",
"      Osteoarthritis of the knee",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/63/35835\">",
"       Effects of osteoarthritis",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28645?source=related_link\">",
"      Patient information: Arthritis and exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/3/11314?source=related_link\">",
"      Patient information: Gout (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/11/7347?source=related_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/21/18769?source=related_link\">",
"      Patient information: Joint infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/46/16098?source=related_link\">",
"      Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/29/21975?source=related_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/59/12211?source=related_link\">",
"      Patient information: Paget disease of bone (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/17/3345?source=related_link\">",
"      Patient information: Shoulder osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/30/21987?source=related_link\">",
"      Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/13/21717?source=related_link\">",
"      Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_3_43059="Olsalazine: Drug information";
var content_f42_3_43059=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Olsalazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/36/44611?source=see_link\">",
"    see \"Olsalazine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/17/16659?source=see_link\">",
"    see \"Olsalazine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dipentum&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F203248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dipentum&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F203280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      5-Aminosalicylic Acid Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F203250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Ulcerative colitis:",
"     </b>",
"     Oral: 1 g/day in 2 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F203251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dipentum&reg;: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F203231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food in evenly divided doses.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F203230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance of remission of ulcerative colitis in patients intolerant to sulfasalazine",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F203287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Olsalazine may be confused with OLANZapine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dipentum&reg; may be confused with Dilantin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F203278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Diarrhea (11% to 17%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (2%), dizziness/vertigo (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2%), pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain/cramps (10%), nausea (5%), bloating (2%), stomatitis (1%), vomiting (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alkaline phosphatase increased, Alopecia, ALT increased, anemia, angioedema, aplastic anemia, AST increased, bilirubin increased, blood in stool, blurred vision, bronchospasm, cholestatic hepatitis, cholestatic jaundice, chest pain, chills, cirrhosis, dehydration, dry eyes, dyspnea, dysuria, eosinophilia, epigastric discomfort, erythema, erythema nodosum, fever, flare of symptoms, flatulence, GGT increased, heart block (second degree), hematuria, hemolytic anemia, hepatitis, hepatic failure, hepatic necrosis, hot flashes, hypertension, impotence, insomnia, interstitial nephritis, interstitial pneumonia, irritability, jaundice, Kawasaki-like syndrome, LDH increased, leukopenia, lymphopenia, menorrhagia, mood swings, muscle cramps, myalgia, myocarditis, nephrotic syndrome, neutropenia, orthostatic hypotension, palpitation, pancreatitis, pancytopenia, paresthesia, pericarditis, peripheral edema, peripheral neuropathy, photosensitivity, proteinuria, rectal bleeding, rectal discomfort, reticulocytosis, rigors, tachycardia, thrombocytopenia, tinnitus, tremor, urinary frequency, watery eyes, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F203234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to olsalazine, salicylates, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F203217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Colitis: May exacerbate symptoms of colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: A common adverse effect is diarrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with severe allergies or asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: 5-ASA Derivatives may decrease the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: 5-ASA Derivatives may enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin (Low Molecular Weight): 5-ASA Derivatives may enhance the adverse/toxic effect of Heparin (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiopurine Analogs: 5-ASA Derivatives may decrease the metabolism of Thiopurine Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: 5-ASA Derivatives may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5357680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated fetal developmental toxicities. There are no well-controlled studies in pregnant women. Use during pregnancy only if clearly necessary.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F203254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5357682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The active metabolite, 5-aminosalicylic acid may pass into breast milk. Diarrhea has been reported in breast-fed infants whose mothers took olsalazine.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F203236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F203235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Dipentum Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $719.66",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F203226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, hepatic function, renal function; stool frequency",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dipentum (AE, AR, AT, AU, BH, CH, CY, DE, DK, EG, FI, FR, GB, GR, HN, HU, IE, IL, IQ, IR, IT, JO, KP, KW, LB, LY, NL, NO, NZ, OM, PT, QA, SA, SE, SY, TR, YE, ZA);",
"     </li>",
"     <li>",
"      Rasal (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F203216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mesalamine (5-aminosalicylic acid) is the active component of olsalazine; the specific mechanism of action of mesalamine is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF); action appears topical rather than systemic.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F203233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &lt;3%; very little intact olsalazine is systemically absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily via colonic bacteria to active drug, 5-aminosalicylic acid (5-ASA)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 54 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces; urine (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kornbluth A and Sachar DB, &ldquo;Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2010, 105(3):501-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/3/43059/abstract-text/20068560/pubmed\" id=\"20068560\" target=\"_blank\">",
"        20068560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9717 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43059=[""].join("\n");
var outline_f42_3_43059=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203247\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203248\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203280\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203250\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203251\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203228\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203213\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203231\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203230\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203287\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203278\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203234\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203217\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299787\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203222\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203224\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5357680\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203254\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5357682\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203236\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203235\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203226\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038710\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203216\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203233\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9717\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9717|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/36/44611?source=related_link\">",
"      Olsalazine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/17/16659?source=related_link\">",
"      Olsalazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_3_43060="Troubleshooting problems with noninvasive positive pressure ventilation";
var content_f42_3_43060=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Troubleshooting problems with noninvasive positive pressure ventilation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43060/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43060/contributors\">",
"     Nicholas S Hill, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43060/contributors\">",
"     Naomi R Kramer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43060/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43060/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43060/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43060/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/3/43060/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive positive pressure ventilation (NPPV) is now commonly used, especially at night, to assist ventilation in patients with a variety of neuromuscular and chest wall diseases. Most patients have some difficulty adapting to nocturnal use of NPPV, although occasional patients adapt within days. Facilitating adjustment to NPPV is important as regular use of NPPV has been shown to lengthen survival in patients with neuromuscular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, greater than four hours of use per night has been associated with increased CO",
"    <sub>",
"     2",
"    </sub>",
"    responsiveness and lower PaCO",
"    <sub>",
"     2",
"    </sub>",
"    levels when compared to less than four hours per night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approaches to resolving the most common side effects of NPPV and to addressing failure of NPPV to improve gas exchange are reviewed here. The indications for and the initiation of nocturnal and daytime NPPV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/36/41543?source=see_link\">",
"     \"Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33896?source=see_link\">",
"     \"Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27095?source=see_link\">",
"     \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MASK INTOLERANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mask discomfort is the most commonly encountered problem for patients adapting to NPPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/3\">",
"     3",
"    </a>",
"    ]. The practitioner should ensure that mask fit is optimal and that minimal strap tension is used to control air leaking. Trials with different types of interfaces may help, such as the \"bubble\" mask, gel masks, nasal \"pillows,\" custom-fit masks, or even oronasal masks or mouthpieces. The patient should not be forced to use the mask for more time than can be tolerated, and should be encouraged to attempt adaptation for at least several weeks or months before giving up. Adaptation can include wearing the mask for brief, but progressively longer periods while watching TV or participating in another distracting activity. Despite these efforts, a minority of patients may be unable to tolerate the sensation of a foreign body strapped to the face, and alternative noninvasive ventilators should be tried. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27095?source=see_link\">",
"     \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NASAL CONGESTION OR DRYNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both nasal congestion and dryness occur commonly during NPPV, sometimes in the same patient. These complaints tend to be seasonal (dryness worse during the winter months) and should be treated symptomatically.",
"   </p>",
"   <p>",
"    In-line heated humidification has become standard and has reduced the nasal dryness problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/4\">",
"     4",
"    </a>",
"    ]. Both the warmth and increased humidity tend to enhance comfort with the airflow. The heated humidifier may also decrease nasal resistance to airflow, which is helpful for patients with concomitant obstructive sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/5\">",
"     5",
"    </a>",
"    ]. The heater may be adjusted to increase and decrease the humidity of the incoming air as needed depending on the local environmental conditions, the pressures at which the ventilator is set, and patient preference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/6\">",
"     6",
"    </a>",
"    ]. Pass-over humidifiers (in which the gas passes over the surface of water) are most often used with pressure-limited ventilators, in order to avoid the drop in pressure that could occur with pass-through humidifiers (in which the gas is bubbled through water). Insulation around the tubing or heated wires within may also help decrease condensation inside the tube, known as \"rain-out.\" Condensation in the tube seems to be particularly problematic in cold climates where the indoor temperatures are often lower at night.",
"   </p>",
"   <p>",
"    Dryness may also respond to nasal saline and water based nasal gels. These thicker gels can be applied in a thin layer along the inside of the nose and can help with mucosal discomfort. These gels are also helpful to decrease local irritation, when using the nasal pillow interface.",
"   </p>",
"   <p>",
"    Nasal congestion may be ameliorated by use of inhaled nasal glucocorticoids or antihistamine decongestant combinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NASAL BRIDGE REDNESS OR ULCERATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal bridge redness or ulceration is caused by excessive mask tension on the nasal bridge. This usually results from efforts to reduce air leaking around the mask, which may irritate the eyes. Minimizing strap tension usually alleviates the problem and can be achieved by using foam rubber \"spacers,\" applying artificial skin (eg, Duoderm&reg;, Restore&reg;), or switching to alternative masks such as the \"bubble\" mask or nasal \"pillows.\" Alternating between mask and nasal pillows may also allow irritation at one site (eg, bridge of nose or facial skin) to resolve while another contact site (eg, inside the nostril) is used. However, the patient needs to be comfortable with both interfaces for this to be effective.",
"   </p>",
"   <p>",
"    Some patients develop acneiform skin rashes where the mask contacts the skin. Low potency corticosteroid creams, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    lotion may be helpful. Washing the face with a mild soap prior to application of the mask may help as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GASTRIC INSUFFLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients notice abdominal distention and flatulence in association with NPPV use. These symptoms are usually tolerable and transient, and do not warrant changes in settings. Intolerable distention is infrequent, probably because pressures used during NPPV rarely exceed 25 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O. However, a reduction in inflation pressure or addition of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/35/33332?source=see_link\">",
"     simethicone",
"    </a>",
"    may help if intolerable symptoms occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     AIR LEAKING THROUGH THE MOUTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leakage of air through the mouth is universal among users of nasal NPPV. Patients can often be satisfactorily ventilated despite such leakage, and no special measures need be taken. Pressure-limited ventilators are able to compensate for leaks by sustaining airflow to maintain mask pressure. Leak compensation during volume-limited ventilation requires an upward adjustment in tidal volume. This may result in some narrowing of the glottis, so that the proportion of air entering the lower airways becomes smaller as ventilator minute volume is increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Air-leaking through the mouth also contributes to sleep arousals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/8\">",
"     8",
"    </a>",
"    ], oxygen desaturations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/9\">",
"     9",
"    </a>",
"    ], and mouth dryness. One study, for example, found that desaturations associated with air leaks disrupted sleep architecture or resulted in arousals 75 percent of the time in seven kyphoscoliotic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/9\">",
"     9",
"    </a>",
"    ]. On the other hand, another showed that NPPV adequately assists nocturnal ventilation in most patients despite air leaking during the majority of sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Should the leak be sufficient to interfere with ventilatory assistance or sleep, or to cause mouth dryness, addition of a chin strap may help. An oronasal mask may also be tried, but only with an anti-asphyxia valve. These masks tend to be less well tolerated than nasal masks for chronic applications, and air leaking around the mask at the chin seal may replace mouth leaking. Choosing an oral-nasal mask that seals under the chin may improve mask stability and reduce leakage.",
"   </p>",
"   <p>",
"    Mouthpiece ventilation will eliminate problems with air leaking through the mouth, but air leaking through the nose may still occur and necessitate use of nasal pledgets. Although mouthpieces may interfere with swallowing, aspiration pneumonia has not been reported as a complication. Some mouthpieces are designed to be expectorated, but with strapped-on mouthpieces in quadriplegic patients, anti-asphyxia valves should be in place to prevent rebreathing in the event of ventilator failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FAILURE TO IMPROVE DAYTIME GAS EXCHANGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients have improvements in gas exchange within weeks of initiating NPPV. If such improvement does not occur, upward adjustments in inspiratory pressure or tidal volume, ventilator rate, duration of ventilator use, or a combination of these changes may be helpful.",
"   </p>",
"   <p>",
"    Rebreathing has been identified as a potential problem when blood gases fail to improve during use of portable pressure support-type ventilators (such as BiPAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/10\">",
"     10",
"    </a>",
"    ]. This is attributable to the use of passive exhalation valves that rely upon bias flow to flush CO",
"    <sub>",
"     2",
"    </sub>",
"    from the single ventilator tube during exhalation. Use of EPAP greater than 4 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (to assure adequate bias flow), switching to a nonrebreather valve, or use of masks with in-mask exhalation ports may help, although leakage through the mouth during nasal ventilation usually minimizes the problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43060/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reasons for nonimproving blood gases other than poor patient compliance include excessive air leakage during inspiration or failure to eliminate apneas. Follow-up nocturnal monitoring in the sleep lab or at home is used to detect these problems. Some positive pressure units have the ability to measure the amount of leak, respiratory events (including apneas, hypopneas, flow limitations, and vibration or snoring) and hours of use, which may provide helpful data for further troubleshooting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     WORSENING GAS EXCHANGE AFTER INITIAL STABILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worsening of gas exchange after initial stabilization is often encountered among patients with slowly progressive neuromuscular diseases. Pulmonary function studies and arterial blood gas measurements are obtained periodically to assess for deterioration. Frequency of follow-up depends on whether patients are starting therapy (every few weeks), stable on therapy (twice yearly), or deteriorating clinically (more often). Arterial blood gases need not be obtained at every visit in stable patients, but checking serum bicarbonate may be helpful as an indicator of changes in PaCO",
"    <sub>",
"     2",
"    </sub>",
"    .",
"   </p>",
"   <p>",
"    Gradual increases in inspiratory pressure, tidal volume, ventilator rate, or amount of daytime use are often indicated to compensate for deteriorating pulmonary function. Problems with the equipment, such as a worn mask that no longer seals well or holes in the tubing, may contribute to ineffective therapy. Routine equipment maintenance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    replacement are advisable. Follow-up nocturnal monitoring may also be helpful to determine whether air leaking or apneas have become problematic.",
"   </p>",
"   <p>",
"    It is also helpful to review the medication list to determine if new medications, which might contribute to respiratory depression or upper airway obstruction, have been started.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients have some difficulty adapting to nocturnal use of NPPV, although occasional patients adapt within days. Prompt resolution of problems with noninvasive positive pressure ventilation (NPPV) is important to achieving continued use. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common problems with NPPV are irritation at contact sites, nasal dryness, and air leaks through the mouth and at contact sites. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Irritation at the interface contact sites can often be alleviated by local measures, alternating interfaces, and avoiding over-tightening of the mask. Nasal dryness is treated with intranasal application of saline spray or gel and also use of heated humidification with or without insulation of the tubing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nasal congestion or dryness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nasal congestion often responds to nasal glucocorticoids or antihistamine decongestant combinations, when indicated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nasal congestion or dryness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mouth leaks are decreased by use of a chinstrap or by changing to an oronasal mask. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Air leaking through the mouth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pressure-limited ventilators are often able to compensate for leaks by sustaining airflow to maintain mask pressure. Leak compensation during volume-limited ventilation requires an upward adjustment in tidal volume. The increase in tidal volume may result in some narrowing of the glottis, which may increase the air leak or gastric insufflation without increasing the effective ventilation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Air leaking through the mouth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients have improvements in gas exchange within weeks of initiating NPPV. If such improvement does not occur, upward adjustments in inspiratory pressure or tidal volume, ventilator rate, duration of ventilator use, or a combination of these changes may be helpful. Follow-up nocturnal monitoring in the sleep lab or at home is used to detect problems with untreated apneas and persistent air leaks. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Failure to improve daytime gas exchange'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary function studies and arterial blood gas measurements are typically obtained at six to twelve month intervals or sooner if the patient's clinical status worsens. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Worsening gas exchange after initial stabilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Worsening of gas exchange after initial stabilization is often encountered among patients with slowly progressive neuromuscular diseases and may necessitate gradual increases in inspiratory pressure, tidal volume, ventilator rate, or amount of daytime use. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Worsening gas exchange after initial stabilization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43060/abstract/1\">",
"      Simonds AK. Recent advances in respiratory care for neuromuscular disease. Chest 2006; 130:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43060/abstract/2\">",
"      Nickol AH, Hart N, Hopkinson NS, et al. Mechanisms of improvement of respiratory failure in patients with restrictive thoracic disease treated with non-invasive ventilation. Thorax 2005; 60:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43060/abstract/3\">",
"      Hill, NS. Complications of noninvasive mask ventilation. Respir Care 1997; 42:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43060/abstract/4\">",
"      Mador MJ, Krauza M, Pervez A, et al. Effect of heated humidification on compliance and quality of life in patients with sleep apnea using nasal continuous positive airway pressure. Chest 2005; 128:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43060/abstract/5\">",
"      Richards GN, Cistulli PA, Ungar RG, et al. Mouth leak with nasal continuous positive airway pressure increases nasal airway resistance. Am J Respir Crit Care Med 1996; 154:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43060/abstract/6\">",
"      Holland AE, Denehy L, Buchan CA, Wilson JW. Efficacy of a heated passover humidifier during noninvasive ventilation: a bench study. Respir Care 2007; 52:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43060/abstract/7\">",
"      Jounieaux V, Aubert G, Dury M, et al. Effects of nasal positive-pressure hyperventilation on the glottis in normal sleeping subjects. J Appl Physiol 1995; 79:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43060/abstract/8\">",
"      Meyer TJ, Pressman MR, Benditt J, et al. Air leaking through the mouth during nocturnal nasal ventilation: effect on sleep quality. Sleep 1997; 20:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43060/abstract/9\">",
"      Bach JR, Robert D, Leger P, Langevin B. Sleep fragmentation in kyphoscoliotic individuals with alveolar hypoventilation treated by NIPPV. Chest 1995; 107:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43060/abstract/10\">",
"      Ferguson GT, Gilmartin M. CO2 rebreathing during BiPAP ventilatory assistance. Am J Respir Crit Care Med 1995; 151:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43060/abstract/11\">",
"      Schettino GP, Chatmongkolchart S, Hess DR, Kacmarek RM. Position of exhalation port and mask design affect CO2 rebreathing during noninvasive positive pressure ventilation. Crit Care Med 2003; 31:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43060/abstract/12\">",
"      Hill NS, Carlisle C, Kramer NR. Effect of a nonrebreathing exhalation valve on long-term nasal ventilation using a bilevel device. Chest 2002; 122:84.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5123 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43060=[""].join("\n");
var outline_f42_3_43060=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MASK INTOLERANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NASAL CONGESTION OR DRYNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NASAL BRIDGE REDNESS OR ULCERATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GASTRIC INSUFFLATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AIR LEAKING THROUGH THE MOUTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FAILURE TO IMPROVE DAYTIME GAS EXCHANGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      WORSENING GAS EXCHANGE AFTER INITIAL STABILIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33896?source=related_link\">",
"      Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/36/41543?source=related_link\">",
"      Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27095?source=related_link\">",
"      Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_3_43061="Etoposide: Patient drug information";
var content_f42_3_43061=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Etoposide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     see \"Etoposide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/17/41240?source=see_link\">",
"     see \"Etoposide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Toposar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14225985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Etoposide Injection USP;",
"     </li>",
"     <li>",
"      Vepesid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4090502",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may irritate the vein. It may burn the skin if the drug leaks from the vein when it is given. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702091",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to etoposide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation or swelling where the shot was given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May not be able to get pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3860450",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing and low blood pressure can happen if the shot is given too fast.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store capsules in a refrigerator.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12458 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FF084CEA57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43061=[""].join("\n");
var outline_f42_3_43061=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169278\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14225985\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027164\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027166\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027165\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027170\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027171\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027173\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027168\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027169\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027174\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027175\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=related_link\">",
"      Etoposide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/17/41240?source=related_link\">",
"      Etoposide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_3_43062="Group B streptococcal infection in pregnant women";
var content_f42_3_43062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Group B streptococcal infection in pregnant women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43062/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43062/contributors\">",
"     Karen M Puopolo, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43062/contributors\">",
"     Lawrence C Madoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43062/contributors\">",
"     Carol J Baker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43062/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43062/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43062/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43062/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/3/43062/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group B streptococcus (GBS; Streptococcus agalactiae) is a gram-positive coccus that frequently colonizes the human genital and gastrointestinal tracts, as well as the upper respiratory tract of young infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is an important cause of illness in infants, pregnant women, and adults with underlying medical conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In pregnant women and postpartum women, GBS is a frequent cause of asymptomatic bacteriuria, urinary tract infection, upper genital tract infection (ie, intraamniotic infection or chorioamnionitis), postpartum endometritis (8 percent), pneumonia (2 percent), puerperal sepsis (2 percent), and bacteremia without a focus (31 percent). It also can cause focal infections such as pneumonia, meningitis, and endocarditis, albeit rarely. The serotype distribution of invasive GBS infection in pregnant women is similar to that of early-onset neonatal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GBS infection in pregnant women will be reviewed here. The microbiology of GBS; GBS infection in neonates, young infants, and nonpregnant adults; and prevention strategies through chemoprophylaxis and vaccination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9621?source=see_link\">",
"     \"Group B streptococcus: Virulence factors and pathogenic mechanisms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=see_link\">",
"     \"Group B streptococcal infection in neonates and young infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36936?source=see_link\">",
"     \"Group B streptococcal infections in nonpregnant adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/31/2552?source=see_link\">",
"     \"Management of the infant whose mother has received group B streptococcal chemoprophylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40984?source=see_link\">",
"     \"Vaccines for the prevention of group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBS infections in pregnant women include urinary tract infection, upper genital tract infection, intraamniotic infection, endometritis, and bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Invasive maternal infection with GBS is associated with pregnancy loss and preterm delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Prior to the widespread use of maternal intrapartum chemoprophylaxis, maternal colonization with GBS conferred an increased risk of chorioamnionitis, and early postpartum infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. There does not appear to be an association between maternal GBS colonization during pregnancy and preterm delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the CDC surveillance study including data collected from 1999 to 2005, the rate of invasive infection (defined as isolation of GBS from a blood or other usually sterile body site, excluding urine) in pregnant women was 0.12 per 1000 live births (range 0.11 to 0.14 per 1000 births) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/4\">",
"     4",
"    </a>",
"    ]. Upper genital tract infection accounted for approximately one-half of cases, isolated bacteremia occurred in one-third of cases, and GBS was isolated from maternal blood in approximately one-half of cases. Among women for whom pregnancy outcome data were available, approximately one-half of the maternal GBS infections led to fetal death, neonatal infections, neonatal death, or pregnancy loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13868378\">",
"    <span class=\"h1\">",
"     COLONIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonization of pregnant women by GBS is a major risk factor for neonatal GBS infection. Issues related to management of colonization and antibiotic prophylaxis for prevention of neonatal infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2461192\">",
"    <span class=\"h1\">",
"     INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Urinary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBS is a frequent cause of asymptomatic bacteriuria, cystitis, and pyelonephritis during pregnancy. Meta-analyses of the impact of asymptomatic bacteriuria in pregnancy demonstrate an association between untreated, asymptomatic bacteriuria (independent of the bacterial species) with progression to pyelonephritis, and with low birth weight or preterm delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The risk of adverse outcome is decreased with antibiotic treatment of asymptomatic bacteriuria in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic GBS bacteriuria in pregnancy is a marker for heavy genital colonization with GBS and, as such, is associated with increased risk of upper genital tract infection and postpartum endometritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. Although Escherichia coli is the most frequently isolated organism in bacteriuria, cystitis, and pyelonephritis in pregnancy, GBS is isolated in 7 to 30 percent of pregnancy-associated cases of asymptomatic bacteriuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/19/42295?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to the adult with asymptomatic bacteriuria\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Asymptomatic bacteriuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic bacteriuria is identified by screening urine cultures that are obtained during prenatal visits. At least one screening culture should be obtained during early pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/16\">",
"     16",
"    </a>",
"    ]. Asymptomatic bacteriuria in pregnancy is as defined separately for nonpregnant adults (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/19/42295?source=see_link\">",
"     \"Approach to the adult with asymptomatic bacteriuria\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The utility of treating GBS bacteriuria at colony counts &le;10",
"    <sup>",
"     5",
"    </sup>",
"    prior to 35 weeks gestation is controversial; some favor this approach to prevent the subsequent development of pyelonephritis and to prevent preterm delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/17\">",
"     17",
"    </a>",
"    ]. In a prospective study of 69 women at 27 to 31 weeks of gestation with GBS bacteriuria, treatment at all colony counts significantly decreased the rates of preterm labor (5 versus 38 percent) and preterm rupture of the membranes (11 versus 53 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/18\">",
"     18",
"    </a>",
"    ]. In a retrospective study of 305 women in early pregnancy (122 with bacteriuria of any colony count and 183 without bacteriuria), an association was observed between untreated GBS bacteriuria and chorioamnionitis at delivery [adjusted odds ratio 7.2; 95% CI 2.4-21.2] [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment consists of antibiotic therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , penicillin, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    . These drugs have not been associated with an increased risk of adverse pregnancy outcome or teratogenic effects. The recommended duration of therapy is three to seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/16\">",
"     16",
"    </a>",
"    ]. Sterile urine must be documented after treatment, and periodic screening cultures should be obtained throughout the pregnancy to identify recurrent bacteriuria.",
"   </p>",
"   <p>",
"    Genital colonization with GBS persists despite adequate therapy for GBS bacteriuria. Women with documented GBS bacteriuria should not be screened for GBS",
"    <span class=\"nowrap\">",
"     rectal/vaginal",
"    </span>",
"    colonization later in pregnancy but should be considered GBS colonized and receive intrapartum chemoprophylaxis at the time of delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystitis is diagnosed by a positive urine culture in the clinical setting of urinary frequency, urgency, and dysuria without fever. It is treated with the same oral antibiotic regimens as asymptomatic GBS bacteriuria (discussed in the preceding section). A repeat urine culture demonstrating clearance of the organism, and periodic repeat cultures for bacteriuria should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pyelonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyelonephritis during pregnancy is diagnosed by a positive urine culture in the clinical setting of fever, urinary symptoms,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    flank pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    costovertebral angle tenderness. In a series of 440 cases of pyelonephritis in pregnancy, GBS accounted for 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/19\">",
"     19",
"    </a>",
"    ]. Treatment includes intravenous hydration and intravenous antibiotics (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or a cephalosporin). If GBS is identified as the cause of pyelonephritis, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    may be administered for a total duration of 10 days, tailored to evidence of clinical improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/40/43657?source=see_link\">",
"     \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intraamniotic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraamniotic infection (IAI), also called chorioamnionitis, is an infection of the amniotic fluid, membranes, placenta,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decidua [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/21\">",
"     21",
"    </a>",
"    ]. Clinical manifestations include fever, uterine tenderness, maternal and fetal tachycardia, purulent amniotic fluid, and maternal leukocytosis.",
"   </p>",
"   <p>",
"    Microbiologic and pathologic criteria for GBS intraamniotic infection include isolation of GBS from culture of placenta, amniotic fluid or amniotic membranes, or from fetal parts in case of pregnancy loss. However, these tissues are frequently contaminated during delivery. An uncontaminated amniotic fluid culture can be obtained by amniocentesis prior to rupture of the fetal membranes. After delivery, the best procedure for placental culture is to peel the amnion off the chorion for a significant amount of fetal surface, and then swab the exposed (and untouched) surface with a sterile swab several times before using the swab for culture inoculation. Fetal cultures can be performed on blood from the umbilical vessels or",
"    <span class=\"nowrap\">",
"     tissues/body",
"    </span>",
"    fluids collected at autopsy.",
"   </p>",
"   <p>",
"    Treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=see_link&amp;anchor=H14#H14\">",
"     \"Intraamniotic infection (chorioamnionitis)\", section on 'Maternal management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endometritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonization with GBS significantly increases the risk of developing postpartum endometritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/7\">",
"     7",
"    </a>",
"    ]. In studies of endometritis, GBS has been identified as a single pathogen in 2 to 14 percent of cases but is more commonly a component of polymicrobial infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/22\">",
"     22",
"    </a>",
"    ]. Endometritis is treated with broad-spectrum antibiotics including anaerobic coverage (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    alone). In cases of life-threatening endometritis or incipient sepsis, broader antibiotic coverage, for example with a carbapenem",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=see_link&amp;anchor=H12#H12\">",
"     \"Postpartum endometritis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of obstetric patients in the 1970s, GBS was the second most common cause of bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/23\">",
"     23",
"    </a>",
"    ]. In a Finnish review of women with peripartum sepsis in the 1990s, GBS was the single most common organism isolated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/24\">",
"     24",
"    </a>",
"    ]. Both studies demonstrated a variety of aerobic and anaerobic gram-positive and gram-negative pathogens other than GBS, suggesting that empiric therapy for suspected bacteremia must consist of broad-spectrum therapy that includes anaerobic coverage. Since implementation of maternal intrapartum GBS chemoprophylaxis, data on the distribution of organisms causing peripartum bacteremia have been lacking. A study of 195 peripartum bacteremia bacterial isolates in the era of screening-based GBS prophylaxis (2000-2008) demonstrated that only 4 percent of blood culture isolates were due to GBS. E. coli and enterococci accounted for over half of all isolates, and 13 percent of isolates were anaerobic species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GBS bacteremia is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36936?source=see_link\">",
"     \"Group B streptococcal infections in nonpregnant adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBS rarely has been associated with a variety of unusual peripartum infections such as maternal meningitis (both antepartum and postpartum), endocarditis, abdominal abscess, and necrotizing fasciitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/22,26,27\">",
"     22,26,27",
"    </a>",
"    ], following both live births and elective pregnancy termination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43062/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. These are discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36936?source=see_link\">",
"     \"Group B streptococcal infections in nonpregnant adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/42/42657?source=see_link\">",
"       \"Patient information: Group B streptococcal disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/63/11248?source=see_link\">",
"       \"Patient information: Group B streptococcus and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91617854\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group B streptococcus (GBS; Streptococcus agalactiae) is a gram-positive coccus that frequently colonizes the human genital and gastrointestinal tracts, as well as the upper respiratory tract of young infants. It is an important cause of illness in infants, pregnant women, and adults with underlying medical conditions. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Invasive maternal infection with GBS is associated with pregnancy loss and preterm delivery. Prior to the widespread use of maternal intrapartum chemoprophylaxis, maternal colonization with GBS conferred an increased risk of chorioamnionitis, and early postpartum infection. It is not clear whether there is an association between maternal GBS colonization during pregnancy and fetal loss or preterm delivery. Issues related to management of colonization and antibiotic prophylaxis for prevention of neonatal infection are discussed separately. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=see_link\">",
"       \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      GBS is a frequent cause of asymptomatic bacteriuria, cystitis, and pyelonephritis during pregnancy. There is an association between untreated, asymptomatic bacteriuria (independent of the bacterial species) with progression to pyelonephritis, and with low birth weight or preterm delivery. The risk of adverse outcome is decreased with antibiotic treatment of asymptomatic bacteriuria in pregnancy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Urinary tract'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic GBS bacteriuria in pregnancy is a marker for heavy genital colonization with GBS and, as such, is associated with increased risk of upper genital tract infection and postpartum endometritis. Asymptomatic bacteriuria is identified by screening urine cultures that are obtained during prenatal visits. At least one screening culture should be obtained during early pregnancy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Urinary tract'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Asymptomatic bacteriuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of asymptomatic bacteriuria with GBS consists of antibiotic therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      , penicillin, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      . The recommended duration of therapy is three to seven days. Sterile urine must be documented after treatment, and periodic screening cultures should be obtained throughout the pregnancy to identify recurrent bacteriuria. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Asymptomatic bacteriuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genital colonization with GBS persists despite adequate therapy for GBS bacteriuria. Women with documented GBS bacteriuria should not be screened for GBS",
"      <span class=\"nowrap\">",
"       rectal/vaginal",
"      </span>",
"      colonization later in pregnancy but should be considered persistently GBS colonized and receive intrapartum chemoprophylaxis at the time of delivery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=see_link\">",
"       \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cystitis is diagnosed by a positive urine culture in the clinical setting of urinary frequency, urgency, and dysuria without fever. It is treated with the same oral antibiotic regimens as asymptomatic GBS bacteriuria. A repeat urine culture demonstrating clearance of the organism and periodic repeat cultures for bacteriuria should be obtained. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cystitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pyelonephritis during pregnancy is diagnosed by a positive urine culture in the clinical setting of fever, urinary symptoms,",
"      <span class=\"nowrap\">",
"       nausea/vomiting,",
"      </span>",
"      flank pain,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      costovertebral angle tenderness. Treatment includes intravenous hydration and intravenous antibiotics. If GBS is identified as the cause of pyelonephritis, treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      may be administered for a total duration of 10 days, tailored to evidence of clinical improvement. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pyelonephritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other infections associated with GBS include intraamniotic infection (chorioamnionitis), endometritis, and bacteremia. Rare peripartum infections include maternal meningitis (both antepartum and postpartum), endocarditis, abdominal abscess, and necrotizing fasciitis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Intraamniotic infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Endometritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Bacteremia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Other infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Edwards MS, Nizet V, Baker CJ. Group B Streptococcal Infections. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.419.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/2\">",
"      Eichenwald EC. Perinatally transmitted neonatal bacterial infections. Infect Dis Clin North Am 1997; 11:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/3\">",
"      Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/4\">",
"      Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/5\">",
"      Regan JA, Klebanoff MA, Nugent RP, et al. Colonization with group B streptococci in pregnancy and adverse outcome. VIP Study Group. Am J Obstet Gynecol 1996; 174:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/6\">",
"      Krohn MA, Hillier SL, Baker CJ. Maternal peripartum complications associated with vaginal group B streptococci colonization. J Infect Dis 1999; 179:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/7\">",
"      Zaleznik DF, Rench MA, Hillier S, et al. Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. Clin Infect Dis 2000; 30:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/8\">",
"      Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/9\">",
"      Prevention of perinatal group B streptococcal disease: A public health perspective. Centers for Disease Control and Prevention (published erratum appears in MMWR Morb Mortal Wkly Rep 1996; 45:679). MMWR Morb Mortal Wkly Rep 1996; 45(RR-7):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/10\">",
"      Valkenburg-van den Berg AW, Sprij AJ, Dekker FW, et al. Association between colonization with Group B Streptococcus and preterm delivery: a systematic review. Acta Obstet Gynecol Scand 2009; 88:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/11\">",
"      Romero R, Oyarzun E, Mazor M, et al. Meta-analysis of the relationship between asymptomatic bacteriuria and preterm delivery/low birth weight. Obstet Gynecol 1989; 73:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/12\">",
"      Mittendorf R, Williams MA, Kass EH. Prevention of preterm delivery and low birth weight associated with asymptomatic bacteriuria. Clin Infect Dis 1992; 14:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/13\">",
"      Anderson BL, Simhan HN, Simons KM, Wiesenfeld HC. Untreated asymptomatic group B streptococcal bacteriuria early in pregnancy and chorioamnionitis at delivery. Am J Obstet Gynecol 2007; 196:524.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/14\">",
"      Wood EG, Dillon HC Jr. A prospective study of group B streptococcal bacteriuria in pregnancy. Am J Obstet Gynecol 1981; 140:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/15\">",
"      Persson K, Bjerre B, Elfstr&ouml;m L, et al. Group B streptococci at delivery: high count in urine increases risk for neonatal colonization. Scand J Infect Dis 1986; 18:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/16\">",
"      Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005; 40:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/17\">",
"      Aungst M, King J, Steele A, Gordon M. Low colony counts of asymptomatic group B streptococcus bacteriuria: a survey of practice patterns. Am J Perinatol 2004; 21:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/18\">",
"      Thomsen AC, M&oslash;rup L, Hansen KB. Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour. Lancet 1987; 1:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/19\">",
"      Hill JB, Sheffield JS, McIntire DD, Wendel GD Jr. Acute pyelonephritis in pregnancy. Obstet Gynecol 2005; 105:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/20\">",
"      ACOG educational bulletin. Antimicrobial therapy for obstetric patients. Number 245, March 1998 (replaces no. 117, June 1988). American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1998; 61:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/21\">",
"      Hitti J, Tarczy-Hornoch P, Murphy J, et al. Amniotic fluid infection, cytokines, and adverse outcome among infants at 34 weeks' gestation or less. Obstet Gynecol 2001; 98:1080.",
"     </a>",
"    </li>",
"    <li>",
"     Isada NB, Grossman JH. Perinatal Infections. In: Obstetrics: Normal and Problem Pregnancies, Gabbe SG, Niebyl JR, Simpson JL (Eds), Churchill Livingstone, New York 1991. p.1276.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/23\">",
"      Blanco JD, Gibbs RS, Castaneda YS. Bacteremia in obstetrics: clinical course. Obstet Gynecol 1981; 58:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/24\">",
"      Kankuri E, Kurki T, Carlson P, Hiilesmaa V. Incidence, treatment and outcome of peripartum sepsis. Acta Obstet Gynecol Scand 2003; 82:730.",
"     </a>",
"    </li>",
"    <li>",
"     Cape AV, Puopolo KM, Taylor C, Tuomala R. Peripartum bacteremia in the era of group B streptococcus prophylaxis. Society for Gynecologic Investigation, presented March 27, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/26\">",
"      Guerin JM, Leibinger F, Mofredj A, Ekherian JM. Streptococcus B meningitis in post-partum. J Infect 1997; 34:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/27\">",
"      Braun TI, Pinover W, Sih P. Group B streptococcal meningitis in a pregnant woman before the onset of labor. Clin Infect Dis 1995; 21:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/28\">",
"      Deziel PJ, McGuire N, Brown PD. Group B streptococcal meningitis complicating elective abortion: report of 2 cases. Clin Infect Dis 2000; 31:E23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43062/abstract/29\">",
"      Palys EE, Li J, Gaut PL, Hardy WD. Tricuspid valve endocarditis with Group B Streptococcus after an elective abortion: the need for new data. Infect Dis Obstet Gynecol 2006; 2006:43253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3170 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43062=[""].join("\n");
var outline_f42_3_43062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H91617854\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13868378\">",
"      COLONIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2461192\">",
"      INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Urinary tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cystitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intraamniotic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endometritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91617854\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/19/42295?source=related_link\">",
"      Approach to the adult with asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36936?source=related_link\">",
"      Group B streptococcal infections in nonpregnant adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9621?source=related_link\">",
"      Group B streptococcus: Virulence factors and pathogenic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/31/2552?source=related_link\">",
"      Management of the infant whose mother has received group B streptococcal chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/42/42657?source=related_link\">",
"      Patient information: Group B streptococcal disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/63/11248?source=related_link\">",
"      Patient information: Group B streptococcus and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/40/43657?source=related_link\">",
"      Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40984?source=related_link\">",
"      Vaccines for the prevention of group B streptococcal disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_3_43063="Overview of treatment approaches for hepatocellular carcinoma";
var content_f42_3_43063=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of treatment approaches for hepatocellular carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43063/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43063/contributors\">",
"     Eddie K Abdalla, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43063/contributors\">",
"     Keith E Stuart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43063/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43063/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43063/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43063/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43063/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/3/43063/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) is an aggressive tumor that often occurs in the setting of chronic liver disease and cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .) It is typically diagnosed late in its course, and the median survival following diagnosis is approximately 6 to 20 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43063/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the mainstay of therapy is surgical resection, the majority of patients are not eligible because of tumor extent or underlying liver dysfunction.",
"   </p>",
"   <p>",
"    Several other treatment modalities are available, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Liver transplantation",
"     </li>",
"     <li>",
"      Radiofrequency ablation (RFA) and microwave ablation",
"     </li>",
"     <li>",
"      Percutaneous ethanol or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      ablation",
"     </li>",
"     <li>",
"      Transarterial chemoembolization (TACE)",
"     </li>",
"     <li>",
"      Radioembolization",
"     </li>",
"     <li>",
"      Cryoablation",
"     </li>",
"     <li>",
"      Radiation therapy and stereotactic radiotherapy",
"     </li>",
"     <li>",
"      Systemic chemotherapy and molecularly targeted therapies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Options are determined both by disease extent and the severity of underlying liver disease, which limits the tolerance to any therapy (medical, interventional or surgical). For patients with cirrhosis, the Child-Pugh classification (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ) is used most widely to stratify patients according to their underlying liver disease, although other measures are increasingly used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12858?source=see_link\">",
"     \"Assessing surgical risk in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This monograph provides an overview of the approaches to treatment of HCC. Detailed discussions on individual treatment options are available. (See appropriate topic reviews). Issues surrounding the diagnosis of HCC and screening for the disease in patients at risk are addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=see_link\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT ALGORITHMS FOR HCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general approach to treatment of HCC is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef57014 \" href=\"mobipreview.htm?40/37/41567\">",
"     algorithm 1",
"    </a>",
"    ). The suggested approach is useful for conceptualizing the various treatment options that are available for individual patients but may not be applicable in all settings. Attempts to generate algorithmic approaches to the treatment of HCC are difficult for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      New treatments and indications for various treatments are evolving rapidly.",
"     </li>",
"     <li>",
"      Therapeutic approaches tend to vary based upon the available expertise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Using tumor stage to select treatment is complicated by the fact that many of the staging systems (including the TNM staging system of the American Joint Committee on Cancer [AJCC]) (",
"      <a class=\"graphic graphic_table graphicRef63333 \" href=\"mobipreview.htm?1/45/1757\">",
"       table 2",
"      </a>",
"      ) are based upon surgical findings; surgery is applicable to only about 5 percent of the United States population. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25992?source=see_link\">",
"       \"Staging and prognostic factors in hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Others recommend exclusive use of the Barcelona Clinic Liver Cancer (BCLC) staging system&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43063/abstract/2\">",
"     2",
"    </a>",
"    ], which classifies patients with HCC into four categories: early, intermediate, advanced, and terminal (",
"    <a class=\"graphic graphic_algorithm graphicRef69566 \" href=\"mobipreview.htm?11/36/11855\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43063/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this algorithm is limited particularly with respect to Barcelona stage B and C patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       Milano/Mazzaferro",
"      </span>",
"      criteria for liver transplantation for HCC (ie, solitary tumor &le;5 cm or up to three tumors all &le;3 cm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/3/43063/abstract/5\">",
"       5",
"      </a>",
"      ]) are not included explicitly even though they are widely accepted. According to the Barcelona algorithm, only some patients with three nodules &le;3 cm (those without \"associated diseases\") should undergo liver transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/3/43063/abstract/2\">",
"       2",
"      </a>",
"      ]. Although there is debate about expanding criteria for transplantation for HCC, there is no debate about the utility of Milano criteria, which have been adopted by the United Network for Organ Sharing (UNOS) and other worldwide organ sharing networks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H4#H4\">",
"       \"Liver transplantation for hepatocellular carcinoma\", section on 'Indications for transplantation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=see_link\">",
"       \"Patient selection for liver transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A second issue is that the Barcelona algorithm does not address the value of resection for some subgroups of patients with HCC who may potentially benefit from this approach, including some patients defined as being \"early stage\" (with a single tumor size &gt;2 cm or multiple nodules) and \"intermediate stage\" (patients who have multinodular tumors but a good performance status) (",
"      <a class=\"graphic graphic_algorithm graphicRef69566 \" href=\"mobipreview.htm?11/36/11855\">",
"       algorithm 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/3/43063/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Large tumor size does not impact survival when vascular invasion is absent (eg, T1 tumors according to the TNM staging system of the AJCC) (",
"      <a class=\"graphic graphic_table graphicRef63333 \" href=\"mobipreview.htm?1/45/1757\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/3/43063/abstract/6\">",
"       6",
"      </a>",
"      ]. Further, patients with T2 tumors (solitary tumor with vascular invasion or multiple tumors, none more than 5 cm) also may be suitable candidates for resection when liver function permits [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/3/43063/abstract/6\">",
"       6",
"      </a>",
"      ]. Others have shown benefit from hepatic resection for patients with single HCCs over 5 cm in diameter, and even selected patients with tumors &ge;10 cm. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link&amp;anchor=H4#H4\">",
"       \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Preoperative assessment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=see_link&amp;anchor=H969400084#H969400084\">",
"       \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\", section on 'Preoperative evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Hepato-Pancreato-Biliary Association",
"    <span class=\"nowrap\">",
"     (AHPBA)/American",
"    </span>",
"    Joint Commission on Cancer (AJCC) Consensus Conference on HCC in 2002 concluded that no single staging system could be used to accurately stage patients across the spectrum of HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43063/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the",
"    <span class=\"nowrap\">",
"     AHPBA/AJCC",
"    </span>",
"    Second Consensus Conference on HCC of 2010, it was again concluded that no single staging system is applicable to all patients with HCC, and the Conference urged against use of a regional staging system because it precludes comparison between centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43063/abstract/8\">",
"     8",
"    </a>",
"    ]. The consensus advised use of the BCLC classification (",
"    <a class=\"graphic graphic_algorithm graphicRef69566 \" href=\"mobipreview.htm?11/36/11855\">",
"     algorithm 2",
"    </a>",
"    ) in medical patients with advanced liver disease who are not candidates for liver transplantation or resection (with advice of caution among Barcelona stage B and C patients, some of whom might be considered for resection or transplantation) and concluded that the",
"    <span class=\"nowrap\">",
"     AJCC/UICC",
"    </span>",
"    classification is valid for HCC staging among patients undergoing liver resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25992?source=see_link&amp;anchor=H8#H8\">",
"     \"Staging and prognostic factors in hepatocellular carcinoma\", section on 'Choice of staging system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these reasons, we prefer the approach outlined in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef57014 \" href=\"mobipreview.htm?40/37/41567\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;What follows is a brief overview of the available treatment options, including usual",
"    <span class=\"nowrap\">",
"     eligibility/ineligibility",
"    </span>",
"    criteria for individual approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially curative partial hepatectomy is the optimal treatment for HCC in patients with adequate liver functional reserve. The ideal patient for resection has a solitary HCC confined to the liver that shows no radiographic evidence of invasion of the hepatic vasculature, no evidence of portal hypertension, and well-preserved hepatic function. Long-term relapse-free survival rates average 40 percent or better, and five-year survival rates as high as 90 percent are reported in carefully selected patients.",
"   </p>",
"   <p>",
"    The preoperative evaluation should focus on the likelihood of disease being confined to the liver, and whether the anatomic constraints of the intrahepatic tumor and underlying liver function will permit resection. Although many surgeons restrict eligibility for resection to patients with tumors that are &le;5 cm in diameter, there is no general rule regarding tumor size for selection of patients for resection. Patients with a solitary HCC without vascular invasion have a similar survival probability regardless of tumor size, although patients with smaller tumors tend to have a better outcome.",
"   </p>",
"   <p>",
"    According to the current",
"    <span class=\"nowrap\">",
"     TNM/UICC",
"    </span>",
"    staging system for HCC (",
"    <a class=\"graphic graphic_table graphicRef63333 \" href=\"mobipreview.htm?1/45/1757\">",
"     table 2",
"    </a>",
"    ), most consider stage IIIB, IIIC, IVA or IVB disease to be incurable by resection. These stages are defined by invasion of a major portal or hepatic vein, direct invasion of organs other than the gallbladder, perforation of the visceral peritoneum, and nodal as well as distant metastases. However, hepatic resection for stages IIIB, IIIC, and IVA disease may be considered in a center of excellence because clinical benefits and long-term survival can be achieved in a properly selected, though admittedly small, minority of patients.",
"   </p>",
"   <p>",
"    Although the rare situation of tumor rupture of an HCC suggests a high likelihood of peritoneal seeding and a poor outcome from resection, this is not inevitable. Several retrospective series suggest a low but defined long-term survival rate following resection in such situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43063/abstract/5\">",
"     5",
"    </a>",
"    ]. The most common approach is initial control of bleeding (which may require embolization or emergency surgery) followed by a formal staging evaluation, and a subsequent attempt at resection, if feasible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=see_link\">",
"     \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of hepatic reserve is paramount to selection for resection. Perioperative mortality is twice as high in cirrhotic as in noncirrhotic patients unless proper patient selection is applied. For patients with cirrhosis, surgical resection is most safely performed in those with Child-Pugh class A disease (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ) who have a normal bilirubin and well preserved liver function. Patients with Child-Pugh class A liver function who require major resection should undergo liver volumetry, and portal vein embolization should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link&amp;anchor=H8#H8\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Assessment of hepatic reserve'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link&amp;anchor=H1061867819#H1061867819\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Portal vein embolization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=see_link\">",
"     \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resection as an option for patients with HCC and Child-Pugh B cirrhosis remains controversial.",
"   </p>",
"   <p>",
"    The influence of hepatic function on outcomes in patients with HCC can be illustrated by the CLIP (Cancer of the Liver Italian Program) staging classification, which incorporates tumor stage as well as hepatic function to predict survival in HCC (",
"    <a class=\"graphic graphic_table graphicRef69726 \" href=\"mobipreview.htm?7/51/7996\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link&amp;anchor=H4#H4\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Preoperative assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=see_link&amp;anchor=H969400084#H969400084\">",
"     \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\", section on 'Preoperative evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all patients who are considered for liver transplantation are unresectable because of the degree of underlying liver dysfunction rather than tumor extent; in fact, liver transplantation can be described as appropriate for patients with earlier stage HCC and advanced liver disease. Orthotopic liver transplantation (OLT) is a suitable option for patients with liver disease (usually cirrhosis) who would not tolerate liver resection and who have a solitary HCC &le;5 cm in diameter or up to three separate lesions none of which is larger than 3 cm, no evidence of gross vascular invasion, and no regional nodal or distant metastases.",
"   </p>",
"   <p>",
"    When these selection criteria are strictly applied, excellent overall three- to four-year actuarial (75 to 85 percent) and recurrence-free survival rates (83 to 92 percent) can be achieved, although these series represent highly selected cases. In carefully selected patients undergoing OLT for HCC, long-term survival is similar or only slightly worse than survival for patients undergoing OLT for non-malignant causes. Other more extended criteria are being considered to widen the indications for OLT, but these extended criteria have not yet been universally adopted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H23#H23\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Expanded transplant criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A major disadvantage with OLT (in addition to the need for lifelong immunosuppression with its attendant risks) is the long waiting time for donor organs. Shortage of donor livers has necessitated the development of allocation schema, whereby priority for donor organs is given to the most severely ill patients. In the United States, liver allocation for adults is based upon the \"model for end stage liver disease\" or MELD score, a statistical model predicting survival in patients with cirrhosis. A diagnosis of HCC increases the priority score for donor organs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link&amp;anchor=H13#H13\">",
"     \"Model for End-stage Liver Disease (MELD)\", section on 'Patients with hepatocellular carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, even with higher priority MELD scores, waiting times for a donor organ may be many months. Although bridging therapy with TACE, RFA, or partial hepatectomy may be considered while a patient is on the waiting list for an OLT, the benefit of any of these approaches is controversial. Living donor transplantation is being applied, although this approach is also controversial. Waiting time is obviously much shorter, and results seem to be at least as good as with deceased donor livers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H10#H10\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Bridging therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H21#H21\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Living donor transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;RFA involves the local application of radiofrequency thermal energy to the lesion, in which a high frequency alternating current moves from the tip of an electrode into the tissue surrounding that electrode. As the ions within the tissue attempt to follow the change in the direction of the alternating current, their movement results in frictional heating of the tissue. As the temperature within the tissue becomes elevated beyond 60&ordm;C, cells begin to die, resulting in a region of necrosis surrounding the electrode.",
"   </p>",
"   <p>",
"    RFA is a reasonable option for patients who do not meet resectability criteria for HCC and yet are candidates for a liver-directed procedure based upon the presence of liver-only disease. Although there is no absolute tumor size beyond which RFA should not be considered, the best outcomes are in patients with a single tumor &lt;4 cm in diameter. For cirrhotic patients, some clinicians restrict RFA to those with Child-Pugh class A or B severity only (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ). As noted above, RFA has also been used as a &ldquo;bridging&rdquo; therapy in patients awaiting liver transplantation to reduce the rate of dropout because of tumor progression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link&amp;anchor=H13#H13\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\", section on 'Radiofrequency ablation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H10#H10\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Bridging therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of RFA relative to surgical resection for patients with potentially resectable HCC remains controversial. Few retrospective series report long-term outcomes from RFA, and there are no randomized trials that directly compare the two treatments. Most clinicians consider that surgery is preferable, if it is feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Percutaneous ethanol or acetic acid ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with RFA, PEI is often considered for patients with small HCCs who are not candidates for resection due to their poor functional hepatic reserve. Before the advent of RFA, PEI was the most widely accepted, minimally invasive method for treating such patients. Although it is low cost, requires a minimal amount of equipment, and has good clinical results, the greater efficacy of RFA has supplanted its use in many institutions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link&amp;anchor=H950876927#H950876927\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\", section on 'RFA versus PEI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar results have been achieved with the percutaneous injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    , which may have fewer side effects than ethanol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link&amp;anchor=H950877150#H950877150\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\", section on 'Percutaneous acetic acid injection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Transarterial chemoembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that the majority of the blood supply to HCCs is derived from the hepatic artery has led to the development of techniques designed to eliminate the tumor's blood supply or to administer cytotoxic chemotherapy directly to the tumor. Transarterial chemoembolization (TACE) involves the injection of a chemotherapeutic agent, with or without lipiodol or a procoagulant material, into the hepatic artery. Lipiodol is an oily contrast agent that promotes intratumoral retention of chemotherapy drugs. A more recent method of chemoembolization involves the use of drug-eluting polyvinyl alcohol microspheres (&ldquo;beads&rdquo;), which seems to cause less toxicity with similar efficacy. Simultaneous or sequential occlusion of the hepatic artery until stagnation of blood flow to the tumor occurs may result in greater antitumor efficacy than chemotherapy alone.",
"   </p>",
"   <p>",
"    TACE is used most often for the treatment of large unresectable HCCs that are not amenable to other treatments such as resection or RFA; its use as a \"bridging therapy\" prior to transplant is common. Bland particle embolization alone (ie, without chemotherapy) has also been used for both unresectable and locally recurrent HCC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=see_link&amp;anchor=H1248650293#H1248650293\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\", section on 'Transarterial embolization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=see_link&amp;anchor=H1248650349#H1248650349\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\", section on 'Drug-eluting beads'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H11#H11\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Chemoembolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Absolute contraindications to this technique include the absence of hepatopetal blood flow (portal vein thrombosis), encephalopathy, and biliary obstruction. Relative contraindications include a variety of other factors including, but not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum bilirubin &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Lactate dehydrogenase &gt;425",
"      <span class=\"nowrap\">",
"       unit/L",
"      </span>",
"     </li>",
"     <li>",
"      Aspartate aminotransferase &gt;100",
"      <span class=\"nowrap\">",
"       unit/L",
"      </span>",
"     </li>",
"     <li>",
"      Tumor burden involving &gt;50 percent of the liver",
"     </li>",
"     <li>",
"      Cardiac or renal insufficiency",
"     </li>",
"     <li>",
"      Ascites, recent variceal bleed, or significant thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cryoablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoablation, the application of alternating freeze-thaw cycles through the use of a cryoprobe inserted directly into the tumor, has been most frequently applied in patients who are determined to have unresectable HCC intraoperatively. RFA has supplanted the use of percutaneous cryoablation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link&amp;anchor=H1248647730#H1248647730\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\", section on 'Cryoablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The place of external beam radiation therapy (RT) among other treatment options for patients with unresectable HCC has yet to be defined. HCC is a radiosensitive tumor, but it is located in an extremely radiosensitive organ. As a whole, the liver can only tolerate about 20 Gy, although newer techniques using three dimensional conformal treatment planning or stereotactic focusing may permit the guided delivery of up to 100 Gy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=see_link&amp;anchor=H1248650377#H1248650377\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\", section on 'External beam RT with and without TACE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Stereotactic radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic body radiation therapy (SBRT) is a technique in which a single (sometimes called stereotactic radiosurgery) or limited number of high dose radiation fractions are delivered to a small, precisely-defined target by using multiple, non-parallel radiation beams. The beams converge precisely on the target lesion, minimizing radiation exposure to adjacent normal tissue. This targeting allows treatment of small or moderated sized tumors in extracranial sites in either a single or limited number of dose fractions.",
"   </p>",
"   <p>",
"    Stereotactic approaches to RT are increasingly being used for treatment of metastatic liver tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=see_link&amp;anchor=H6#H6\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\", section on 'Liver metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experience with stereotactic body radiotherapy or radiosurgery for primary liver tumors is limited but increasing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=see_link&amp;anchor=H1248650405#H1248650405\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\", section on 'IMRT and stereotactic body radiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Radioembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative means of delivering focal radiation employs radioactive isotopes (eg, iodine-131 [131I]- labeled lipiodol or yttrium-90 [90Y]-tagged glass microspheres) that are delivered selectively to the tumor via the hepatic artery. Early reports suggest that radioembolization using intrahepatic artery administration of (90Y)-tagged glass microspheres is safe, and induces objective responses in patients with unresectable HCC. However, longer-term follow-up of these studies and additional experience is needed with this technique. Ultimately, randomized controlled trials will be needed to compare the efficacy of this approach with other nonsurgical therapies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=see_link&amp;anchor=H1248650419#H1248650419\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\", section on 'Radioembolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1021979043\">",
"    <span class=\"h3\">",
"     Molecularly targeted therapy: sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially reported in 2007, the multicenter European randomized SHARP trial demonstrated a modest though statistically significant survival benefit for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    (a multitargeted tyrosine kinase inhibitor) over supportive care alone in patients with advanced HCC. These data established sorafenib monotherapy as the new reference standard systemic treatment for advanced HCC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H18#H18\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Sorafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These data have also served to improve the willingness of practitioners to offer systemic therapy to patients with advanced HCC and have prompted optimism in the future potential of drug combinations. A preliminary report of a randomized phase II trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    versus doxorubicin alone suggested benefit for combined therapy; however, whether these results are better than can be achieved using sorafenib alone will require a randomized trial in which the control arm is sorafenib. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H20#H20\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Sorafenib plus doxorubicin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cytotoxic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy has not been used routinely for patients with advanced HCC for a number of reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatocellular cancer has been considered to be a relatively chemotherapy-refractory tumor. This may be in part due to the high rate of expression of drug resistance genes, including p-glycoprotein, glutathione-S-transferase, heat shock proteins, and mutations in p53.",
"     </li>",
"     <li>",
"      It can be difficult to gauge benefit from chemotherapy in patients with advanced HCC since survival is most often determined not by tumor aggressiveness or the impact of a systemic treatment, but by the degree of hepatic dysfunction. Systemic chemotherapy is usually not well tolerated by patients with significant underlying hepatic dysfunction.",
"     </li>",
"     <li>",
"      Clinical investigations of chemotherapy in advanced HCC have been undertaken in diverse patient populations. As an example, patients in Asian studies tend to be significantly younger, with well compensated cirrhosis due more often to chronic hepatitis B than hepatitis C, while North American or European patients with HCC are typically over 60, with alcoholic cirrhosis, more often hepatitis C than hepatitis B, and comorbid illnesses. Not only does this interfere with chemotherapy tolerance, dose, and the reported side effect profile, but in studies applying strict entry criteria, the results may be applicable only to the small minority of Western patients who have well preserved hepatic function. Moreover, chemotherapy may have less efficacy in patients with significant cirrhosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these issues, emerging data suggest a modest degree of antitumor efficacy for several cytotoxic agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    combination drug regimens, and a trial of chemotherapy may be warranted in many individuals, particularly if they have normal underlying liver. There are insufficient data to routinely recommend any one regimen as a standard of care. In general, cytotoxic therapy should be reserved for medically appropriate patients with adequate hepatic function, preferably administered within the context of a clinical trial. This may be especially appropriate in otherwise healthy patients with rapidly growing disease, who have no local treatment alternatives. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H5#H5\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Systemic chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reactivation of viral hepatitis may occur in patients with HCC who are undergoing intensive systemic chemotherapy, so it is important to maintain antiviral medications. This topic is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=see_link\">",
"       \"Patient information: Liver cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HCC is typically an aggressive tumor that arises in the setting of underlying chronic liver disease in most cases. Although the preferred therapy is surgical resection, the majority of patients are not eligible because of tumor extent or underlying liver dysfunction. For patients who are not surgically resectable, liver transplantation is the only other potentially curative option.",
"     </li>",
"     <li>",
"      For patients who are not eligible for resection or liver transplantation, treatment options include local nonsurgical methods of tumor ablation (RFA, PEI), transarterial chemoembolization, radiation therapy, and systemic therapy. The selection of treatment is determined by the severity of underlying liver disease, the size and distribution of the intrahepatic tumors, the vascular supply, and the patient&rsquo;s overall performance status.",
"     </li>",
"     <li>",
"      A general approach to treatment of HCC is shown in the figure (",
"      <a class=\"graphic graphic_algorithm graphicRef57014 \" href=\"mobipreview.htm?40/37/41567\">",
"       algorithm 1",
"      </a>",
"      ). The suggested approach is useful for conceptualizing the various treatment options that are available for individual patients but may not be applicable in all settings.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43063/abstract/1\">",
"      A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43063/abstract/2\">",
"      Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43063/abstract/3\">",
"      Llovet JM, Br&uacute; C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43063/abstract/4\">",
"      Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43063/abstract/5\">",
"      Liu CL, Fan ST, Lo CM, et al. Management of spontaneous rupture of hepatocellular carcinoma: single-center experience. J Clin Oncol 2001; 19:3725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43063/abstract/6\">",
"      Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43063/abstract/7\">",
"      Henderson JM, Sherman M, Tavill A, et al. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford) 2003; 5:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43063/abstract/8\">",
"      Vauthey JN, Dixon E, Abdalla EK, et al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010; 12:289.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2489 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43063=[""].join("\n");
var outline_f42_3_43063=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT ALGORITHMS FOR HCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surgical resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Percutaneous ethanol or acetic acid ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transarterial chemoembolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cryoablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Stereotactic radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Radioembolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1021979043\">",
"      - Molecularly targeted therapy: sorafenib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cytotoxic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2489\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2489|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?40/37/41567\" title=\"algorithm 1\">",
"      Treatment algorithm for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/36/11855\" title=\"algorithm 2\">",
"      Barcelona Rx algorithm HCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2489|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/21/8540\" title=\"table 1\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/45/1757\" title=\"table 2\">",
"      TNM staging HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/51/7996\" title=\"table 3\">",
"      CLIP score for HCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12858?source=related_link\">",
"      Assessing surgical risk in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=related_link\">",
"      Liver transplantation for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=related_link\">",
"      Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=related_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25992?source=related_link\">",
"      Staging and prognostic factors in hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=related_link\">",
"      Surgical management of potentially resectable hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=related_link\">",
"      Systemic treatment for advanced hepatocellular carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_3_43064="Neurologic complications of cancer treatment with biologic agents";
var content_f42_3_43064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic complications of cancer treatment with biologic agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43064/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43064/contributors\">",
"     Eudocia Quant Lee, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43064/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43064/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43064/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43064/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43064/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/3/43064/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications of anticancer therapy may result from direct toxic effects on the nervous system, or indirectly from drug-induced metabolic derangements or cerebrovascular disorders. Their recognition is important because of potential confusion with metastatic disease, paraneoplastic syndromes or comorbid neurologic disorders that do not require dose reduction or discontinuation. If the neurologic disorder is caused by the chemotherapy, discontinuation of the offending agent may prevent irreversible injury.",
"   </p>",
"   <p>",
"    Here we discuss the neurologic complications associated with biologic agents, including both biological response modifiers and monoclonal antibodies. The neurological complications associated with cytotoxic chemotherapy agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link\">",
"     \"Neurologic complications of platinum-based chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOLOGICAL RESPONSE MODIFIERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In recent years there has been increasing interest in the use of biological response modifiers in cancer treatment. Frequently, they are used in combination with conventional chemotherapeutic agents (biochemotherapy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alpha (IFN-a) is useful for a number of cancers including hairy cell leukemia, Kaposi's sarcoma, melanoma, multiple myeloma, chronic myeloid leukemia (CML) and low grade lymphoma. However, IFN-a is associated with a variety of substantial toxicities, which may limit the ability to deliver a full course of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/1\">",
"     1",
"    </a>",
"    ]. Frequent systemic toxicities include flu-like symptoms (myalgias, nausea, vomiting, arthralgias, fever, chills, and headache) and depression. The flu-like symptoms tend to be worse at the onset of therapy and usually improve with time.",
"   </p>",
"   <p>",
"    Neurotoxicity tends to be dose-related. It is generally mild when low doses of IFN-a are used, as in the adjuvant setting for patients with malignant melanoma. In a detailed evaluation of 37 such patients treated with interferon, the most frequent neurotoxicity was tremor, observed in eight cases (22 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44711?source=see_link&amp;anchor=H2#H2\">",
"     \"Adjuvant immunotherapy for melanoma\", section on 'Clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At higher doses, such as those used for patients with advanced melanoma, IFN-a can cause confusion, lethargy, hallucinations, and seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Although these effects are usually reversible, a permanent dementia or persistent vegetative state may result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More commonly, patients develop a depressive syndrome over weeks to months. Neuropsychiatric symptoms are usually mild to moderate and typically resolve within two to three weeks of IFN discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/5\">",
"     5",
"    </a>",
"    ]. Cognitive impairments involving memory, processing speed, and executive functioning have also been reported in some studies of cancer patients receiving IFN-a [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] but not in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, IFN-a has been associated with oculomotor palsy, sensorimotor neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/9\">",
"     9",
"    </a>",
"    ], myasthenia gravis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/10\">",
"     10",
"    </a>",
"    ], brachial plexopathy, an action tremor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/11\">",
"     11",
"    </a>",
"    ], and polyradiculopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two available preparations of IFN-a (2a and 2b), and their toxicities differ only slightly. The side effect profile of pegylated preparations of either IFN-a, which have a longer half-life, are similar to those observed with standard IFN-a2a and IFN-a2b except that in some studies, neutropenia and thrombocytopenia are slightly more severe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Interferon alfa 2a (Roferon, Pegasys)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of neuropsychiatric disturbances (including depression and suicidal",
"    <span class=\"nowrap\">",
"     behavior/ideation)",
"    </span>",
"    is highly variable with IFN-a2a, but generally over 15 percent. Dizziness (21 percent), irritability (15 percent), and insomnia (14 percent), vertigo (19 percent) and mental status changes (12 percent) are common. In addition, somnolence, lethargy, confusion, and mental impairment may occur. Motor weakness may be seen at high doses (&gt;100 million units) and usually reverses within a few days.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/27/27064?source=see_link\">",
"     Pegylated interferon alfa-2a",
"    </a>",
"    is similar to standard IFN-a2a with respect to safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Interferon alfa-2b (Intron, PEG-Intron)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both IFN-a2b and pegylated IFN-a2b have been associated with depression, anxiety, irritability or emotional lability (4 to 40 percent), somnolence (1 to 33 percent), paresthesias (1 to 21 percent), dizziness (7 to 23 percent), confusion (1 to 12 percent), insomnia (1 to 12 percent), impaired concentration (1 to 14 percent, usually reverses within a few days), amnesia (1 to 14 percent), and hypertonia (5 percent with PEG-Intron). Vertigo has been reported in 8 percent of patients with lymphoma treated with IFN.",
"   </p>",
"   <p>",
"    Although most neurologic side effects of IFN-a2b are similar to IFN-a2a, a particularly high incidence of neuropsychiatric toxicity has been noted in some studies of patients with CML treated with recombinant IFN-a2b. In one study of 91 patients, one-fourth experienced grade 3 or 4 neuropsychiatric toxicity that affected daily functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/14\">",
"     14",
"    </a>",
"    ]. All patients recovered upon withdrawal of IFN-a. Patients with a prior psychiatric history were more likely to develop severe neuropsychiatric toxicity than patients without a psychiatric history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/14\">",
"     14",
"    </a>",
"    ]. In another study of 344 patients with CML, the reported incidence of grade 3 or 4 depression was not elevated (6 percent with recombinant IFN-a2b and 8 percent with pegylated IFN-2b, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Intrathecal interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal administration of IFN-a has been evaluated for the treatment of meningeal and brain tumors, and progressive multifocal leukoencephalopathy. An acute reaction (within hours of the first injection) consists of headache, nausea, vomiting, fever, and dizziness; these usually resolve over 12 to 24 hours. A severe encephalopathy develops in a significant number of patients within several days of the onset of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/16\">",
"     16",
"    </a>",
"    ]. This is dose dependent and tends to be worse in patients who have received cranial irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\", section on 'Investigational intrathecal therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Beta and gamma interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience with interferon beta (IFN-b, Betaseron) and interferon gamma (IFN-g) treatment in oncology patients is limited compared to IFN-a, but the overall toxicity profile with both agents appears to be similar to that of IFN-a. However, the rates of acute and late neurologic adverse events have not been appreciably higher as compared to the control arms from randomized phase III clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in a phase III trial of IFN-g1b plus chemotherapy versus chemotherapy alone for ovarian and peritoneal carcinomas, the reported rates of neurologic side effects were 56 and 54 percent in the IFN-g and chemotherapy alone groups, respectively and psychiatric side effects were 28 versus 23 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures have been reported with interferon gamma in patients with a history of brain metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/19\">",
"     19",
"    </a>",
"    ]. Hypertonia and myasthenia have been reported with IFN-b [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Interleukin-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin 2 (IL-2) has been used both alone and in several biochemotherapy combinations, both with and without IFN, for a number of cancers, particularly renal cell carcinoma and melanoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12522?source=see_link\">",
"     \"Immunotherapy of renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=see_link\">",
"     \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=see_link&amp;anchor=H100471489#H100471489\">",
"     \"Interleukin-2 and other immunotherapies for advanced melanoma\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Toxicity is dose-dependent. Neuropsychiatric complications, which occur in up to 30 to 50 percent of patients, include cognitive changes, delusions, hallucinations, and depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/20\">",
"     20",
"    </a>",
"    ]. Confusion may be a dose-limiting effect of high-dose IL-2 regimens, but it is rarely seen with combination biochemotherapy regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/21\">",
"     21",
"    </a>",
"    ]. Symptoms typically resolve upon termination of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less commonly, transient focal neurologic deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/23\">",
"     23",
"    </a>",
"    ], acute leukoencephalopathy, carpal tunnel syndrome, myositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/24\">",
"     24",
"    </a>",
"    ], myasthenia gravis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/25\">",
"     25",
"    </a>",
"    ], and brachial neuritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/26\">",
"     26",
"    </a>",
"    ] have been reported with IL-2. Administration of interleukin-2 directly into the tumor bed (with lymphokine-activated killer, or LAK cells) for the treatment of gliomas can cause significant cerebral edema, and neurotoxicity appears to be dose limiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One case of grade 5 neurotoxicity has been reported in a patient treated with IL-2 and granulocyte macrophage colony-stimulating factor (GM-CSF). This patient experienced a fatal cerebral hemorrhage associated with thrombocytopenia, leading the authors to recommend extreme caution in using these agents together [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/29\">",
"     29",
"    </a>",
"    ]. Others have not reported excessive neurotoxic effects in patients treated with both agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tumor necrosis factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic administration of tumor necrosis factor-alpha (TNF-a) is limited by toxicity; neurologically, these effects include encephalopathy, transient aphasia, or other focal deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/32\">",
"     32",
"    </a>",
"    ]. As a result, the use of TNF-a in patients with cancer is limited to isolated limb perfusion for patients with advanced sarcoma or melanoma. Isolated limb perfusion with TNF-a is associated with a mild sensory neuropathy that typically begins two to three weeks after perfusion and generally abates after eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27081?source=see_link\">",
"     \"Cutaneous melanoma: Management of in transit metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34007?source=see_link\">",
"     \"Cutaneous melanoma: Management of local recurrence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27354?source=see_link\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Denileukin diftitox",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     Denileukin diftitox",
"    </a>",
"    (Ontak) is a fusion toxin used to treat refractory cutaneous T-cell lymphoma (CTCL). The most common complication is a vascular leak syndrome, but some patients experience headaches, myalgias, dizziness, paresthesias, nervousness, confusion and insomnia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/34\">",
"     34",
"    </a>",
"    ]. In a phase III clinical trial of denileukin diftitox in patients with CTCL, the reported rate of grade 3 or 4 adverse events affecting the central nervous system, including headaches, confusion, and dementia, was 17 to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36410?source=see_link\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MONOCLONAL ANTIBODIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    (Rituxan) is a humanized monoclonal antibody directed against the CD20 antigen that is found on the surface of normal and malignant B lymphocytes. It is used for the treatment of low-grade or follicular B-cell lymphoma, as well as other disorders where B lymphocytes are involved in disease pathogenesis. Neurologic complications are uncommon, but some patients complain of headaches, myalgias, dizziness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], or paresthesias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rare cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients being treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/38\">",
"     38",
"    </a>",
"    ]. In a review of 57 patients who developed PML after rituximab, all patients had received prior therapies with alkylating agents, corticosteroids, purine analogs or drugs to prevent allogeneic stem cell or solid organ graft rejection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has been associated with reversible posterior leukoencephalopathy syndrome (RPLS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tositumomab radioconjugate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/45/29398?source=see_link\">",
"     Tositumomab radioconjugate",
"    </a>",
"    (Iodine-131",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/45/29398?source=see_link\">",
"     tositumomab",
"    </a>",
"    , Bexxar) is one of several anti-CD-20 radioimmunoconjugates used in the treatment of indolent non-Hodgkin lymphoma. These agents deliver targeted radiotherapy to tumor-bearing areas. A minority of treated patients experience headache or myalgias during treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7338?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\", section on 'Radioimmunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    (Herceptin) is a humanized anti-HER2 monoclonal antibody that is used either alone or in combination with cytotoxic agents for the treatment of HER2-overexpressing breast cancer in the metastatic and adjuvant settings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11705?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few patients experience headaches, dizziness and insomnia after infusion of the antibody [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/42\">",
"     42",
"    </a>",
"    ]. Paresthesias and peripheral neuropathy are even less common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351181285\">",
"    <span class=\"h3\">",
"     Trastuzumab emtansine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/16/11527?source=see_link\">",
"     Trastuzumab emtansine",
"    </a>",
"    (T-DM1) is an antibody-drug conjugate that incorporates",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    with the cytotoxic microtubule inhibitor DM1. It is approved for advanced breast cancer in patients previously exposed to trastuzumab and taxanes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22202?source=see_link&amp;anchor=H720673240#H720673240\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'Ado-trastuzumab emtansine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral neuropathy, mainly grade 1 and predominantly sensory, has been reported in 21 to 22 percent of treated patients in clinical trials; it was grade 3 or worse in 1.5 to 2.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/43\">",
"     43",
"    </a>",
"    ]. The drug should be temporarily discontinued for grade 3 or 4 toxicity until resolution to &le;grade 2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    (Avastin) is a humanized monoclonal antibody against VEGF used in the treatment of a variety of cancers. Several clinical trials of bevacizumab combined with chemotherapy suggest a significant increase in the risk of serious arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, and myocardial infarction). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H291526420#H291526420\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Bevacizumab and aflibercept'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reversible posterior leukoencephalopathy syndrome (RPLS) occurs in less than 0.1 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . Symptoms can include headache, seizure, lethargy, confusion, blindness, and other visual and neurologic disturbances. RPLS may be associated with mild to severe hypertension. The onset may occur from 16 hours to one year after initiation of therapy. Symptoms usually resolve with discontinuation of bevacizumab and control of any associated hypertension. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651228679#H1651228679\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Reversible posterior leukoencephalopathy and brain capillary leak syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    increases the risk for bleeding and concerns have been raised about a potential increase in thr risk of intracerebral hemorrhage in patients treated with bevacizumab who have brain metastases or primary brain tumors. However, the available data suggest that rates of serious hemorrhage are low. Patients with a history of treated nonhemorrhagic brain metastases probably should not be excluded from systemic therapy with bevacizumab or other angiogenic therapies as long as they are not on concurrent anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227407#H1651227407\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Intracranial bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in an anticoagulated patient with a recurrent primary brain tumor is more complex and must be based upon a careful assessment of the risk to benefit ratio. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=see_link&amp;anchor=H530204220#H530204220\">",
"     \"Management of recurrent malignant gliomas\", section on 'Side effects'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Rarely, severe optic neuropathy has been reported in brain tumor patients after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/44\">",
"     44",
"    </a>",
"    ]. In a case series of six patients, all had previously received standard chemoradiation, with radiation doses to the optic apparatus that were limited to those generally considered within tolerance levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    (Erbitux) is a chimeric mouse-human antibody against epidermal growth factor that is used in the treatment of head and neck cancer as well as colorectal cancer. In a study of 420 patients with advanced colorectal cancer who received cetuximab monotherapy, 26 percent developed headaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients on cetuximab may develop symptomatic hypomagnesemia, which may lead to severe fatigue, cramps, and somnolence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H35#H35\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'EGFR pathway inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cases of aseptic meningitis have also been reported in association with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H582252\">",
"    <span class=\"h2\">",
"     Brentuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/6/16486?source=see_link\">",
"     Brentuximab vedotin",
"    </a>",
"    is a CD30-directed antibody-drug conjugate that is used for treatment of certain CD30-positive lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27785?source=see_link&amp;anchor=H4185630#H4185630\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\", section on 'Brentuximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38009?source=see_link&amp;anchor=H15846182#H15846182\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\", section on 'Brentuximab vedotin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In clinical trials, 36 to 53 percent of patients treated with brentuximab developed a peripheral neuropathy of any grade; approximately 10 to 14 percent had severe (grade 3 or 4 (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 1",
"    </a>",
"    )) neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. The peripheral neuropathy was mainly sensory and cumulative, but motor neuropathy was also reported. Reversibility was addressed in a phase II trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/51\">",
"     51",
"    </a>",
"    ], in which 15 of 31 patients who developed peripheral neuropathy of any grade had complete resolution at the last safety assessment (48 percent), while 10 others had some improvement. The median time to improvement or resolution was 9.9 weeks after treatment discontinuation.",
"   </p>",
"   <p>",
"    The FDA-approved manufacturer&rsquo;s labeling recommends that dosing be held for new or worsening grade 2 or 3 (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 1",
"    </a>",
"    ) neuropathy, held until improvement to grade 1, then restarted at a lower dose; the drug should be discontinued for grade 4 neuropathy.",
"   </p>",
"   <p>",
"    Rare reports of progressive multifocal leukoencephalopathy (PML) prompted the US FDA to add a black box warning to the drug label regarding this complication in January 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43064/abstract/52\">",
"     52",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications associated with anticancer treatments, including biologic agents, adversely impact quality of life and may limit further therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interferons and high-dose interleukin-2 are associated with neuropsychiatric complications.",
"     </li>",
"     <li>",
"      Rare cases of progressive multifocal leukoencephalopathy have been reported in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , and brentuximab.",
"     </li>",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in combination with chemotherapy are at higher risk for thromboembolic events, including cerebrovascular accidents. Early recognition may help avoid permanent neurologic damage.",
"     </li>",
"     <li>",
"      Up to one-fourth of patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"       denileukin diftitox",
"      </a>",
"      for refractory cutaneous T cell lymphoma develop grade 3 or 4 adverse events affecting the central nervous system (headaches, confusion, and dementia).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127139631\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to recognize Dr. Scott Plotkin, who contributed to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/1\">",
"      Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/2\">",
"      Caraceni A, Gangeri L, Martini C, et al. Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. Cancer 1998; 83:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/3\">",
"      Rohatiner AZ, Prior PF, Burton AC, et al. Central nervous system toxicity of interferon. Br J Cancer 1983; 47:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/4\">",
"      Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/5\">",
"      Lerner DM, Stoudemire A, Rosenstein DL. Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics 1999; 40:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/6\">",
"      Pavol MA, Meyers CA, Rexer JL, et al. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995; 45:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/7\">",
"      Schachter J, Brenner B, Fenig E, et al. Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence. Oncol Rep 1999; 6:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/8\">",
"      Dickinson MD, Barr CD, Hiscock M, Meyers CA. Cognitive effects of pegylated interferon in individuals with primary brain tumors. J Neurooncol 2009; 95:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/9\">",
"      Rutkove SB. An unusual axonal polyneuropathy induced by low-dose interferon alfa-2a. Arch Neurol 1997; 54:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/10\">",
"      Bora I, Karli N, Bakar M, et al. Myasthenia gravis following IFN-alpha-2a treatment. Eur Neurol 1997; 38:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/11\">",
"      Nishihori T, Abdo-Matkiwsky M, Fleishman SB, Blum RH. Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma. Am J Clin Oncol 2005; 28:526.",
"     </a>",
"    </li>",
"    <li>",
"     Delattre J, Vega F, Chen Q. Neurologic complications of immunotherapy. In: Neurologic complications of cancer, Wiley RG (Ed), Marcel Dekker, New York 1995. p.267.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/13\">",
"      Lipton JH, Khoroshko N, Golenkov A, et al. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-na&iuml;ve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma 2007; 48:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/14\">",
"      Hensley ML, Peterson B, Silver RT, et al. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 2000; 18:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/15\">",
"      Michallet M, Maloisel F, Delain M, et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 2004; 18:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/16\">",
"      Meyers CA, Obbens EA, Scheibel RS, Moser RP. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 1991; 68:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/17\">",
"      Bradley JD, Scott CB, Paris KJ, et al. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). Int J Radiat Oncol Biol Phys 2002; 52:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/18\">",
"      Alberts DS, Marth C, Alvarez RD, et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol 2008; 109:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/19\">",
"      Brown TD, Koeller J, Beougher K, et al. A phase I clinical trial of recombinant DNA gamma interferon. J Clin Oncol 1987; 5:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/20\">",
"      Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987; 107:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/21\">",
"      Buzaid AC, Atkins M. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Clin Cancer Res 2001; 7:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/22\">",
"      Petrella T, Quirt I, Verma S, et al. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007; 33:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/23\">",
"      Bernard JT, Ameriso S, Kempf RA, et al. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology 1990; 40:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/24\">",
"      Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer 1995; 76:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/25\">",
"      Fraenkel PG, Rutkove SB, Matheson JK, et al. Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer. J Immunother 2002; 25:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/26\">",
"      Loh FL, Herskovitz S, Berger AR, Swerdlow ML. Brachial plexopathy associated with interleukin-2 therapy. Neurology 1992; 42:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/27\">",
"      Barba D, Saris SC, Holder C, et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989; 70:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/28\">",
"      Hayes RL, Koslow M, Hiesiger EM, et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995; 76:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/29\">",
"      Hotton KM, Khorsand M, Hank JA, et al. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis. Cancer 2000; 88:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/30\">",
"      Correale P, Campoccia G, Tsang KY, et al. Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial. Eur J Cancer 2001; 37:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/31\">",
"      Westermann J, Reich G, Kopp J, et al. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2001; 49:613.",
"     </a>",
"    </li>",
"    <li>",
"     Paleologos N. Complications of chemotherapy. In: Iatrogenic Neurology, Biller J (Ed), Butterworth-Heinemann, Boston 1998. p.439.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/33\">",
"      Drory VE, Lev D, Groozman GB, et al. Neurotoxicity of isolated limb perfusion with tumor necrosis factor. J Neurol Sci 1998; 158:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/34\">",
"      Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/35\">",
"      Maloney DG, Grillo-L&oacute;pez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15:3266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/36\">",
"      Maloney DG, Press OW. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies. Oncology (Williston Park) 1998; 12:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/37\">",
"      Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/38\">",
"      Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/39\">",
"      Mavragani CP, Vlachoyiannopoulos PG, Kosmas N, et al. A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion. Rheumatology (Oxford) 2004; 43:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/40\">",
"      Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/41\">",
"      Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/42\">",
"      Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639.",
"     </a>",
"    </li>",
"    <li>",
"     FDA-approved prescribing information available online at file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf?et_cid=31141095&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f125427lbl.pdf (Accessed on February 25, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/44\">",
"      Sherman JH, Aregawi DG, Lai A, et al. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 2009; 73:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/45\">",
"      Pfeiffer P, Nielsen D, Yilmaz M, et al. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 2007; 46:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/46\">",
"      Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/47\">",
"      Feinstein TM, Gibson MK, Argiris A. Cetuximab-induced aseptic meningitis. Ann Oncol 2009; 20:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/48\">",
"      Nagovskiy N, Agarwal M, Allerton J. Cetuximab-induced aseptic meningitis. J Thorac Oncol 2010; 5:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/49\">",
"      Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/50\">",
"      Shustov AR, Advani R, Brice P, et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma (abstract 961). Blood 2010; 116:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43064/abstract/51\">",
"      Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30:2190.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm287710.htm?source=govdelivery (Accessed on January 13, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2825 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43064=[""].join("\n");
var outline_f42_3_43064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOLOGICAL RESPONSE MODIFIERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Interferon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Interferon alfa 2a (Roferon, Pegasys)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Interferon alfa-2b (Intron, PEG-Intron)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Intrathecal interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Beta and gamma interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Interleukin-2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tumor necrosis factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Denileukin diftitox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MONOCLONAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tositumomab radioconjugate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H351181285\">",
"      - Trastuzumab emtansine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cetuximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H582252\">",
"      Brentuximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H127139631\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2825\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2825|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/35/11836\" title=\"table 1\">",
"      NCI CTCAE grading of neurotoxicity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27081?source=related_link\">",
"      Cutaneous melanoma: Management of in transit metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34007?source=related_link\">",
"      Cutaneous melanoma: Management of local recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12522?source=related_link\">",
"      Immunotherapy of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=related_link\">",
"      Interleukin-2 and other immunotherapies for advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=related_link\">",
"      Management of recurrent malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38009?source=related_link\">",
"      Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11705?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36410?source=related_link\">",
"      Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27354?source=related_link\">",
"      Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7338?source=related_link\">",
"      Treatment of relapsed or refractory follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27785?source=related_link\">",
"      Treatment of relapsed or refractory peripheral T cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_3_43065="Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects";
var content_f42_3_43065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43065/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43065/contributors\">",
"     Philip Janicak, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43065/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43065/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/3/43065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/3/43065/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/3/43065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H182696693\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    for treating mania was discovered in 1949, making it the first medication specifically developed to treat bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/1\">",
"     1",
"    </a>",
"    ]. Lithium remains a mainstay of treatment for bipolar disorder, especially for acute mania and maintenance treatment. In addition, lithium appears to reduce the risk of suicide in patients with bipolar disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H259506193#H259506193\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Reduced risk of suicide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pharmacology, administration, and side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    are reviewed here. Choosing a medication (including lithium) to treat acute mania, hypomania, mixed states, and bipolar depression is discussed separately, as is the choice of medication for maintenance treatment of bipolar disorder, and the epidemiology, clinical manifestations, and diagnosis of bipolar disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"       \"Bipolar disorder in adults: Maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    to treat unipolar major depression is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/50/17192?source=see_link\">",
"     \"Unipolar depression in adults: Treatment with lithium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H136818786\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is a mood disorder that is characterized by episodes of mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ), hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ), and major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ), as well as mixed episodes (major depression concurrent with mania or hypomania) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/2\">",
"     2",
"    </a>",
"    ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic and mixed episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic and mixed episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H385746629\">",
"    <span class=\"h1\">",
"     STRUCTURE AND FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    is the third element of the periodic table, and is a monovalent cation that shares certain properties with sodium, potassium, and calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    &rsquo;s mechanism of action in treating mania and mixed states is unknown. One hypothesis is that it depletes inositol in the central nervous system and dampens neurotransmission dependent upon this second messenger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Other hypotheses are that lithium works by inhibiting the activity of glycogen synthase kinase 3&beta; in regulating an intracellular signaling peptide called Wnt, or by inhibiting overactive protein kinase C intracellular signaling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Lithium appears to affect multiple neurotransmitter systems including norepinephrine, dopamine, serotonin, and glutamate; and second messenger systems including cyclic adenosine monophosphate and cyclic guanosine monophosphate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/5,6,8\">",
"     5,6,8",
"    </a>",
"    ]. In addition, lithium also appears to increase neurogenesis and neuroprotective factors, and in patients with bipolar disorder, increase cortical gray matter and hippocampal volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H446684325\">",
"    <span class=\"h1\">",
"     ROLE IN TREATING BIPOLAR DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two primary considerations in choosing a medication are clinical efficacy and tolerability. These two factors involve issues such as past response to medications, comorbid medical illnesses, concurrent medications, and specific symptoms. Another consideration is cost.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    is one of many medications that can be selected to treat acute mania, hypomania, mixed states, and bipolar and unipolar depression, and is also a potential choice for maintenance treatment of bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/11-19\">",
"     11-19",
"    </a>",
"    ]. The choice of pharmacotherapy for bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H1829248939#H1829248939\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Lithium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H5#H5\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Lithium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    is generally avoided in patients with significant renal disease and often not used during the first trimester of pregnancy. In addition, lithium can significantly affect thyroid function. (See",
"    <a class=\"local\" href=\"#H182696821\">",
"     'Long-term side effects'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/32999?source=see_link\">",
"     \"Renal toxicity of lithium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=see_link&amp;anchor=H1561534#H1561534\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\", section on 'Lithium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42453?source=see_link\">",
"     \"Lithium and the thyroid\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few studies have examined whether certain subgroups of patients respond preferentially to a specific drug. In patients with mixed states or a greater lifetime number of mood episodes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    may be inferior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H446684335\">",
"    <span class=\"h2\">",
"     Reduced risk of suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is associated with a reduced risk of suicide attempts and suicide deaths. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H259506193#H259506193\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Reduced risk of suicide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H446684351\">",
"    <span class=\"h2\">",
"     Severely ill patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with severe mania or mixed states, the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    plus an antipsychotic is often useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/11,24\">",
"     11,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H7954915#H7954915\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Severe manic and mixed episodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H446684761\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absorption, distribution, and elimination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    are well-described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Lithium is rapidly absorbed through the gastrointestinal tract; food does not alter lithium absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/28\">",
"     28",
"    </a>",
"    ]. Peak serum levels occur in one to two hours with standard, immediate release preparations of lithium and within four to five hours with slow release preparations. Absorption of immediate release lithium is complete within six to eight hours, and for slow release preparations in approximately 8 to 12 hours. Lithium is not protein bound and is distributed throughout total body water. Brain levels are highest within two hours of peak serum levels. Steady state is achieved within four to five days after the last dose change.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    is not metabolized and is excreted almost exclusively through the kidneys. Thus, lithium&rsquo;s elimination half-life is determined primarily by renal function. The half-life in healthy young patients is about 24 hours, and increases as renal function declines with age.",
"   </p>",
"   <p>",
"    Additional information about the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     \"Lithium: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182696749\">",
"    <span class=\"h1\">",
"     PRESCRIBING LITHIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several basic points to discuss with patients before prescribing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , including potential side effects, the need to take the medication as prescribed rather than on as-needed basis, and to expect that response and remission may not occur until a few days to weeks have elapsed after a therapeutic",
"    <span class=\"nowrap\">",
"     dose/level",
"    </span>",
"    has been achieved. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182696765\">",
"    <span class=\"h2\">",
"     Lithium dose and serum concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is usually 300 mg two or three times daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/5,29-31\">",
"     5,29-31",
"    </a>",
"    ]. The dose is then increased by 300 to 600 mg every one to five days based upon response, tolerability, and body mass index. The goal is to reach a therapeutic serum level, which generally occurs with a dose of 900 mg to 1800 mg per day. Dose increases generally occur more frequently at the beginning of treatment, and less often as clinicians approach the target dose.",
"   </p>",
"   <p>",
"    The half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is approximately 24 hours. Thus, it takes at least four or five days for serum lithium concentrations to reach steady state after the dose is changed.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    can be dosed either once daily or in a divided dose regimen. Clinicians should start with a twice daily or three times daily dosing schedule to minimize side effects (especially nausea) early in treatment and consolidate the dose schedule to once daily after a number of weeks or months of treatment. Some patients may have to continue taking lithium in two or four divided doses to minimize peak level side effects. However, adherence generally decreases as the frequency of dosing increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The target serum level for acute phase management and maintenance treatment is between 0.8 and 1.2",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (0.8 and 1.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and levels should usually not exceed 1.2",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (1.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients who cannot tolerate a level of 0.8",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (0.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    may respond to a level of 0.6",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (0.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After reaching the estimated therapeutic dose range (generally 900 mg to 1800 mg per day), the serum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    concentration should be checked. Subsequently, a level should be measured five to seven days after each dose increase. In addition, if the dose is not changed and a level not checked for two or more weeks, a level should be checked before increasing the dose. An office-based instrument for fingerstick tests of lithium levels is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    levels should be drawn approximately 12 hours after the last dose (12-hour serum trough level) and generally collected in the morning, before the first dose of the day. Changes in the serum level per unit time are not dramatic 12 hours after the last dose. Thus, a level drawn 11 to 13 hours after the last dose, or even 10 to 14 hours, provides meaningful information. In contrast, a serum level drawn a few hours after lithium ingestion is subject to marked fluctuation if the level is drawn one hour sooner or later, leading to unreliable information.",
"   </p>",
"   <p>",
"    Serum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    levels are closely related to renal function, salt balance, and water balance. Clinicians can expect lithium concentrations to change as follows: &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dehydration (may occur with gastrointestinal viral infections or high fever) causes higher",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      levels",
"     </li>",
"     <li>",
"      Increasing sodium intake causes increased sodium and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      excretion and lower lithium levels",
"     </li>",
"     <li>",
"      Decreased sodium intake causes sodium and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      reabsorption in the proximal tubule and an increase in serum lithium levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is taken once per day, serum concentrations are approximately 25 percent higher compared with levels that are observed when lithium is taken two or three times per day; this is due to changes in renal excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/35\">",
"     35",
"    </a>",
"    ]. Therefore, a once daily lithium level of 1.0",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (1.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    is expected to drop to a level of 0.8",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (0.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    if the patient switches to a divided dose regimen. Virtually all studies examining optimal lithium levels have used divided dose regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H446684831\">",
"    <span class=\"h3\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    in elderly patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16330?source=see_link&amp;anchor=H1137967#H1137967\">",
"     \"Geriatric bipolar disorder: Acute treatment\", section on 'First line medications'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     \"Lithium: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182696772\">",
"    <span class=\"h2\">",
"     Lithium preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple preparations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    are available, varying in dose from 100 to 1000 mg. There is no difference in treatment efficacy or serum concentrations among the various lithium preparations.",
"   </p>",
"   <p>",
"    The most commonly prescribed preparation in the United States contains 300 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    carbonate, which provides 8",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    of lithium. Lithium carbonate is available as a tablet or capsule. In addition, lithium is available as a liquid in the form of lithium citrate for patients who have difficulty swallowing pills. A dose of 5 mL contains 300 mg of lithium.",
"   </p>",
"   <p>",
"    Several slow-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    tablets are available. Slow-release lithium may cause less nausea than conventional, immediate release forms at least in the beginning of treatment, but also a slightly higher incidence of diarrhea, due to more distal gastrointestinal absorption. Slow-release tablets should be swallowed whole, rather than crushed or chewed.",
"   </p>",
"   <p>",
"    Additional information about",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    preparations is discussed separately. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     \"Lithium: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182696779\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    is contraindicated in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Significant renal impairment",
"     </li>",
"     <li>",
"      Sodium depletion",
"     </li>",
"     <li>",
"      Dehydration",
"     </li>",
"     <li>",
"      Significant cardiovascular disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal impairment, sodium depletion, and dehydration increase the risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    toxicity. In addition, lithium can rarely cause sinus node dysfunction (eg, sinus bradycardia and sinoatrial block), atrioventricular node dissociation with atrioventricular block and junctional rhythms, and ventricular premature beats.",
"   </p>",
"   <p>",
"    Psoriasis, which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    exacerbates, is a relative contraindication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182696786\">",
"    <span class=\"h2\">",
"     Lithium toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    levels can lead to toxicity with severe side effects and multisystem dysfunction that can be fatal if not recognized. Lithium toxicity is a clinical diagnosis that is confirmed by serum lithium levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/5\">",
"     5",
"    </a>",
"    ]. Relatively mild toxicity usually does not occur until serum lithium reaches a level of 1.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Levels &ge; 2.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    constitute a medical emergency, even in patients who appear relatively asymptomatic. Symptoms and treatment of toxicity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9225?source=see_link\">",
"     \"Lithium poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    has a narrow therapeutic index, which means that the dose at which it is clinically effective is only slightly lower than the dose at which it becomes toxic. One study found that the mortality rate from lithium toxicity was approximately 25 percent with an acute overdose and 9 percent in patients intoxicated during maintenance therapy; an additional 10 percent in the latter group suffered permanent neurologic damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    intoxication is increased when lithium excretion is impaired. This most commonly occurs with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Underlying renal insufficiency",
"     </li>",
"     <li>",
"      Effective volume depletion",
"     </li>",
"     <li>",
"      Elderly patients (low glomerular filtration rate)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182696793\">",
"    <span class=\"h2\">",
"     Drug interactions with lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications that change renal function, salt balance, or water balance can alter",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    excretion and serum lithium concentrations. Lithium levels must be closely monitored in patients taking these medications. These drug interactions are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increases",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      level",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Thiazide diuretics",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDS) except",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"     </li>",
"     <li>",
"      Angiotensin converting enzyme (ACE) inhibitors",
"     </li>",
"     <li>",
"      Antibiotics tetracyclines and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreases",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      level",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Potassium-sparing diuretics",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      May increase or decrease",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      level",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Loop diuretics",
"     </li>",
"     <li>",
"      Calcium channel blockers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These medications are not contraindicated for patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    . Rather, patients receiving medications that may interact with lithium should have their serum levels monitored more closely. Specific interactions of any particular drug with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182696800\">",
"    <span class=\"h2\">",
"     Laboratory tests and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before prescribing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    and during ongoing treatment, laboratory tests need to be obtained because lithium can adversely affect several organ systems. Management of abnormal test results and adverse effects resulting from lithium are described elsewhere in the topic, as is management of a positive pregnancy test. (See",
"    <a class=\"local\" href=\"#H182696821\">",
"     'Long-term side effects'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H182696969\">",
"     'Pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Prior to beginning",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , the following tests should be obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/11,37\">",
"     11,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinalysis, blood urea nitrogen (BUN), creatinine, thyroid function studies, and calcium",
"     </li>",
"     <li>",
"      Pregnancy test for women of childbearing potential",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG) for patients with risk factors for coronary heart disease, including diabetes mellitus, hypertension, dyslipidemia, and cigarette smoking. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"       \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    levels should be checked five to seven days after the dose is changed. In addition, a lithium level should be checked if a dose increase is under consideration and a level has not been measured for at least two weeks. Patients on steady doses should have their levels checked every 6 to 12 months.",
"   </p>",
"   <p>",
"    In addition to checking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    levels during ongoing treatment, renal, thyroid, and parathyroid function should be monitored as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinalysis, BUN, and creatinine every 2 to 3 months during the first 6 months of therapy, and every 6 to 12 months thereafter (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/32999?source=see_link\">",
"       \"Renal toxicity of lithium\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thyroid function tests once or twice during the first 6 months, and every 6 to 12 months thereafter or more frequently in higher risk patients (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42453?source=see_link\">",
"       \"Lithium and the thyroid\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum calcium is monitored yearly",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182696807\">",
"    <span class=\"h2\">",
"     Lithium side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    can cause many acute and long-term adverse effects that are not necessarily associated with toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182696814\">",
"    <span class=\"h3\">",
"     Acute side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common acute side effects associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/5,6,39-41\">",
"     5,6,39-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nausea",
"     </li>",
"     <li>",
"      Tremor",
"     </li>",
"     <li>",
"      Polyuria (related to nephrogenic diabetes insipidus) and thirst",
"     </li>",
"     <li>",
"      Weight gain",
"     </li>",
"     <li>",
"      Loose stools",
"     </li>",
"     <li>",
"      Cognitive impairment (including apathy, decreased creativity, and changes in verbal learning, memory, and concentration)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some side effects can be managed. Nausea can be reduced by taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    with food. Nausea, tremor, and cognitive dulling are dose-related and may diminish with either dose reduction, or dividing the daily dose to take smaller amounts more often, in order to decrease peak serum levels. Beta blockers may decrease tremor. Diuretics (eg, the potassium-sparing diuretic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    ) may decrease polyuria, but caution must be used because many diuretics alter lithium levels; lithium doses may need to be adjusted and lithium levels checked more often.",
"   </p>",
"   <p>",
"    Severe or a sudden worsening of side effects may be a sign of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    toxicity. (See",
"    <a class=\"local\" href=\"#H182696786\">",
"     'Lithium toxicity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9225?source=see_link\">",
"     \"Lithium poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182696821\">",
"    <span class=\"h3\">",
"     Long-term side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most common long term adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    involve the kidneys and thyroid gland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/5,39\">",
"     5,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68178733\">",
"    <span class=\"h4\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal function is adversely affected by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    and thus monitored with laboratory tests. In a systematic review of lithium toxicity, the findings regarding renal damage were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of four case-control studies found that tubular renal function (expressed as urinary concentrating ability) was significantly reduced by approximately 15 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      may increase the incidence of end-stage renal failure, but the absolute risk appears small; in a cohort study of 3369 patients treated with lithium, renal replacement therapy was required by 0.5 percent, compared with 0.2 percent in the general population. The renal toxicity of lithium is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/32999?source=see_link\">",
"       \"Renal toxicity of lithium\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A meta-analysis of five case-control studies (372 cases treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      and 307 untreated controls) found that glomerular filtration rate was reduced by 6",
"      <span class=\"nowrap\">",
"       mL/minute",
"      </span>",
"      in patients who took lithium compared with controls, but the difference was neither statistically nor clinically significant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    initially reduces the ability of the kidney to concentrate urine, leading to dilute urine and polyuria (nephrogenic diabetes insipidus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/42\">",
"     42",
"    </a>",
"    ]. Over months and years, this functional deficit becomes structural. Biopsy specimens from patients chronically treated with lithium show interstitial fibrosis that is consistent with chronic interstitial nephritis in more severe cases. If patients drink enough when they are thirsty, this is not dangerous. However, this process can lead to increased serum creatinine and, rarely, to progressive renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Thus, monitoring renal function with serial serum creatinine concentrations is an essential part of ongoing lithium therapy. Clinicians should consult a nephrologist and discontinue lithium when the serum creatinine approaches or exceeds 1.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (140",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/44\">",
"     44",
"    </a>",
"    ]. The most important risk factor for renal damage from lithium is repeated episodes of lithium intoxication. It is not clear whether higher mean serum lithium levels correlate with greater risk of renal damage. Taking lithium once per day instead of in divided doses may correlate with less tubular dysfunction, especially if this regimen is instituted early on in treatment before structural tubular changes have occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/45\">",
"     45",
"    </a>",
"    ]. Additional information about renal toxicity and lithium is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/32999?source=see_link\">",
"     \"Renal toxicity of lithium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormal renal function tests are managed in collaboration with a nephrologist to determine the need for further testing, a reduction in the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , or switching to an alternative medication for treating bipolar disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68178740\">",
"    <span class=\"h4\">",
"     Thyroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid function is adversely affected by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    and thus monitored with laboratory tests; lithium can cause goiter, hypothyroidism, chronic autoimmune thyroiditis, and possibly hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/46\">",
"     46",
"    </a>",
"    ]. A meta-analysis of eight case-control studies (869 cases treated with lithium and 578 untreated controls) found that hypothyroidism occurred in significantly more cases than controls (14 versus 2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, lithium increased thyroid stimulation hormone by 4",
"    <span class=\"nowrap\">",
"     iU/mL.",
"    </span>",
"    The adverse effects of lithium on thyroid function and their management are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42453?source=see_link\">",
"     \"Lithium and the thyroid\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neither pretreatment hypothyroidism (presumably treated adequately with T4) nor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -induced hypothyroidism is a contraindication to lithium therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/46\">",
"     46",
"    </a>",
"    ]. Reasonable recommendations are to monitor serum thyrotropin (TSH) and if it rises much above the upper value of normal, to start T4 while continuing the lithium. Consultation with an endocrinologist may also be indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68178747\">",
"    <span class=\"h4\">",
"     Parathyroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    may also cause hypercalcemia, elevated serum parathyroid hormone, and hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/38,47-49\">",
"     38,47-49",
"    </a>",
"    ]. A meta-analysis of 13 case-control studies (730 cases treated with lithium and 699 untreated controls) found that serum calcium concentration was significantly increased in cases by 0.1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    compared with controls, and that lithium was associated hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An elevated calcium level should prompt a serum parathyroid hormone concentration. If the hormone level is abnormal, an endocrine consult is obtained. Hypercalcemia, hyperparathyroidism secondary to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , and measurement of serum calcium are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30361?source=see_link&amp;anchor=H23#H23\">",
"     \"Pathogenesis and etiology of primary hyperparathyroidism\", section on 'Lithium therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Measurement of serum calcium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68179204\">",
"    <span class=\"h4\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    may rarely cause cardiac dysrhythmias in patients without pre-existing cardiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/5,38,39\">",
"     5,38,39",
"    </a>",
"    ]. In addition, lithium may lead to the following abnormalities on the ECG, which may anticipate the onset of dysrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Repolarization abnormalities of the T wave or ST segment",
"     </li>",
"     <li>",
"      Findings consistent with the sick sinus syndrome (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22008?source=see_link&amp;anchor=H11#H11\">",
"       \"Manifestations and causes of the sick sinus syndrome\", section on 'Other'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An unmasked or modulated Brugada pattern (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These ECG findings should prompt a cardiology consult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182696969\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is generally regarded as teratogenic due to increased risks of cardiac defects (eg, Ebstein&rsquo;s anomaly) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/50-52\">",
"     50-52",
"    </a>",
"    ], many authorities consider the absolute risk small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/3/43065/abstract/53-57\">",
"     53-57",
"    </a>",
"    ]. The use of lithium during pregnancy and risks of lithium exposure during pregnancy and breastfeeding are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2874?source=see_link&amp;anchor=H328730#H328730\">",
"     \"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy\", section on 'Refractory patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=see_link&amp;anchor=H1561534#H1561534\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\", section on 'Lithium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38745?source=see_link&amp;anchor=H22#H22\">",
"     \"Use of psychotropic medications in breastfeeding women\", section on 'Lithium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/29/28117?source=see_link\">",
"       \"Lithium: Patient drug information\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The United States National Library of Medicine and National Institutes of Health have created an educational document entitled \"",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    &rdquo; that explains the use of lithium. It is available online at the website",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/druginfo/meds/a681039.html\">",
"     file://www.nlm.nih.gov/medlineplus/druginfo/meds/a681039.html",
"    </a>",
"    , and copies may be printed free of charge. &nbsp;",
"   </p>",
"   <p>",
"    The United States National Institute of Mental Health has a document entitled, &ldquo;Mental Health Medications,&rdquo; that is available online at",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/mental-health-medications/complete-index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/mental-health-medications/complete-index.shtml",
"    </a>",
"    , or through the toll-free number 866-615-6464. Copies may be printed free of charge.",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    or 800-826-3632) is a national organization whose mission is to educate members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    or 800-950-6264) is a similarly structured organization devoted to providing education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182696983\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      is one of many medications that can be selected to treat acute mania, hypomania, mixed states, and bipolar depression, and is also a potential choice for maintenance treatment of bipolar disorder. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"       \"Bipolar disorder in adults: Maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      is a mainstay of treatment for bipolar disorder and may reduce the risk of suicide. (See",
"      <a class=\"local\" href=\"#H182696693\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H446684325\">",
"       'Role in treating bipolar disorder'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H259506193#H259506193\">",
"       \"Bipolar disorder in adults: Maintenance treatment\", section on 'Reduced risk of suicide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      is rapidly absorbed through the gastrointestinal tract. Peak serum levels occur in one to two hours with immediate release preparations of lithium and within four to five hours with slow release preparations. Lithium is distributed throughout total body water. Steady state is achieved within four to five days after the last dose change. Lithium is excreted almost exclusively through the kidneys. The half-life is about 24 hours in healthy young patients, and increases as renal function declines with age. (See",
"      <a class=\"local\" href=\"#H446684761\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The starting dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      is usually 300 mg two or three times daily. The dose should be increased by 300 to 600 mg every one to five days based upon response, tolerability, and body mass index. The goal is to reach a therapeutic serum level, which generally occurs with a dose of 900 mg to 1800 mg per day. Dose increases generally occur more frequently at the beginning of treatment, and less often as clinicians approach the target dose. (See",
"      <a class=\"local\" href=\"#H182696765\">",
"       'Lithium dose and serum concentrations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The target serum level for acute phase management and maintenance treatment is between 0.8 and 1.2",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (0.8 and 1.2",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and levels should not exceed 1.5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (1.5",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Patients who cannot tolerate a level of 0.8",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (0.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      may respond to a level of 0.6",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (0.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H182696765\">",
"       'Lithium dose and serum concentrations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Levels should generally be measured five to seven days after each dose increase. In addition, a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      level should be checked if a dose increase is under consideration and a level has not been measured within the past two weeks. Patients on steady doses should have their levels checked every 6 to 12 months. Lithium levels should be drawn 12 hours after the last dose (12-hour serum trough level) and generally collected in the morning, before the first dose of the day. (See",
"      <a class=\"local\" href=\"#H182696765\">",
"       'Lithium dose and serum concentrations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H182696800\">",
"       'Laboratory tests and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      levels are closely related to renal function, salt balance, and water balance. Dehydration causes higher lithium levels, increasing sodium intake causes lower lithium levels, and decreased sodium intake causes an increase in serum lithium levels. (See",
"      <a class=\"local\" href=\"#H182696765\">",
"       'Lithium dose and serum concentrations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      is contraindicated in patients with significant renal impairment, sodium depletion, dehydration, significant cardiovascular disease. (See",
"      <a class=\"local\" href=\"#H182696779\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Excessive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      levels can lead to toxicity with severe side effects and multisystem dysfunction which can be fatal if not recognized. Lithium toxicity is a clinical diagnosis that is confirmed by serum lithium levels. Relatively mild toxicity usually does not occur until serum lithium reaches a level of 1.5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (1.5",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Levels &ge; 2.5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      constitute a medical emergency, even in patients who appear relatively asymptomatic. (See",
"      <a class=\"local\" href=\"#H182696786\">",
"       'Lithium toxicity'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9225?source=see_link\">",
"       \"Lithium poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many medications can alter",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      concentrations. Lithium levels are increased by thiazide diuretics, nonsteroidal antiinflammatory drugs (NSAIDS) except",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , angiotensin converting enzyme (ACE) inhibitors, tetracyclines, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      . Lithium levels are decreased by potassium-sparing diuretics and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      . Lithium levels are increased or decreased by loop diuretics and calcium channel blockers. (See",
"      <a class=\"local\" href=\"#H182696793\">",
"       'Drug interactions with lithium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to beginning",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , clinicians should obtain a urinalysis, blood urea nitrogen (BUN), creatinine, thyroid function studies, calcium, pregnancy test for women of childbearing potential, and an electrocardiogram (ECG) for patients over age 40. BUN and creatinine should be checked every two to three months during the first six months of therapy, and every 6 to 12 months thereafter. Thyroid function should be checked once or twice during the first six months, and every 6 to 12 months thereafter. (See",
"      <a class=\"local\" href=\"#H182696800\">",
"       'Laboratory tests and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common acute side effects associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      are nausea, tremor, polyuria and thirst, weight gain, loose stools, and cognitive impairment. Severe or a sudden worsening of side effects may be a sign of lithium toxicity. Important long term adverse effects of lithium involve the kidneys and thyroid gland. In addition, cardiac rhythm disturbances have been described; these almost always occur in patients with preexisting cardiac disease. (See",
"      <a class=\"local\" href=\"#H182696807\">",
"       'Lithium side effects'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9225?source=see_link\">",
"       \"Lithium poisoning\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29273947\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Jeffrey Stovall, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/1\">",
"      CADE JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2:349.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     Freeman, MP, Wiegand, CB, Gelenberg, AJ. The American Psychiatric Publishing Textbook of Psychopharmacology, 4th, Schatzberg, AF, Nemeroff CB (Eds),  American Psychiatric Publishing, Inc., 2009. p.697.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/4\">",
"      Malhi GS, Tanious M, Das P, Berk M. The science and practice of lithium therapy. Aust N Z J Psychiatry 2012; 46:192.",
"     </a>",
"    </li>",
"    <li>",
"     Labbate, LA, Fava, M, Rosenbaum, JF, et al. Drugs for treatment of bipolar disorders. In: Handbook of Psychiatric Drug Therapy, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.110.",
"    </li>",
"    <li>",
"     Freeman, MP, Wiegand, et al. Lithium. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th, Schatzberg, AF, Nemeroff, CB (Eds), American Psychiatric Publishing, Inc, Washington, D.C. 2009. p.697.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/7\">",
"      Zarate CA, Manji HK. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 2009; 23:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/8\">",
"      Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord 2009; 11:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/9\">",
"      Chuang DM, Manji HK. In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry 2007; 62:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/10\">",
"      Chiu CT, Chuang DM. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 2010; 128:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/11\">",
"      American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/12\">",
"      Smith LA, Cornelius V, Warnock A, et al. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/13\">",
"      Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11:225.",
"     </a>",
"    </li>",
"    <li>",
"     Hirschfeld, RM. Guideline Watch: Practice guideline for the treatment of patients with bipolar disorder. Arlington, VA; American Psychiatric Association www.psych.org/psych_pract/treatg/pg/prac_guide.cfm (Accessed on May 11, 2007).",
"    </li>",
"    <li>",
"     Keck, PE, McElroy, SL. Treatment of bipolar disorder. In: The American Psychiatric Publishing Textbook of Psychopharmacology , 4th, Schatzberg, AF, Nemeroff, CB (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.1113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/16\">",
"      BALANCE investigators and collaborators, Geddes JR, Goodwin GM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/17\">",
"      Smith LA, Cornelius V, Warnock A, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/18\">",
"      Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/19\">",
"      Vieta E, G&uuml;nther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011; 14:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/20\">",
"      Swann AC, Bowden CL, Calabrese JR, et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999; 156:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/21\">",
"      Swann AC, Bowden CL, Morris D, et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/22\">",
"      McElroy SL, Keck PE Jr, Pope HG Jr, et al. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am J Psychiatry 1992; 149:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/23\">",
"      Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/24\">",
"      Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64:442.",
"     </a>",
"    </li>",
"    <li>",
"     Thummel, KE, et, al. Design and optimization of dosage regimens: pharmacokinetic data (appendix II). In: Goodman &amp; Gilman's Pharmacological Basis of Therapeutics, 11th ed, Brunton, LL, Lazo, JS, Parker, KL (Eds), McGraw-Hill, New York 2006.",
"    </li>",
"    <li>",
"     MedicinesComplete [Internet database]. Pharmaceutical Press, London, 2010 file://www.medicinescomplete.com (Accessed on September 28, 2010).",
"    </li>",
"    <li>",
"     DRUGDEX&reg; System [Internet database]. Greenwood Village, CO, Thomson Reuters (Healthcare) Inc, 2002-2010. (Accessed September 28, 2010).",
"    </li>",
"    <li>",
"     Alda, M. Pharmacokinetics of lithium. In: Lithium in Neuropsychiatry, Bauer, et al (Eds), Informa UK Ltd, United Kingdom 2006. p.321.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/29\">",
"      Griswold KS, Pessar LF. Management of bipolar disorder. Am Fam Physician 2000; 62:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/30\">",
"      Glick ID, Suppes T, DeBattista C, et al. Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Ann Intern Med 2001; 134:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/31\">",
"      Drugs for psychiatric disorders. Treat Guidel Med Lett 2006; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/32\">",
"      Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/33\">",
"      Nolen WA, Weisler RH. The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disord 2013; 15:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/34\">",
"      InstaRead Lithium System. Med Lett Drugs Ther 2005; 47:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/35\">",
"      Lauritsen BJ, Mellerup ET, Plenge P, et al. Serum lithium concentrations around the clock with different treatment regimens and the diurnal variation of the renal lithium clearance. Acta Psychiatr Scand 1981; 64:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/36\">",
"      Hansen HE, Amdisen A. Lithium intoxication. (Report of 23 cases and review of 100 cases from the literature). Q J Med 1978; 47:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/37\">",
"      Jefferson JW. A clinician's guide to monitoring kidney function in lithium-treated patients. J Clin Psychiatry 2010; 71:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/38\">",
"      Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs 2009; 23:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/39\">",
"      Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. Am J Med 2006; 119:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/40\">",
"      Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ. Effects of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry 2009; 70:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/41\">",
"      McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/42\">",
"      Gitlin M. Lithium and the kidney: an updated review. Drug Saf 1999; 20:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/43\">",
"      Jefferson JW. Lithium: a therapeutic magic wand. J Clin Psychiatry 1989; 50:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/44\">",
"      Gitlin MJ. Lithium-induced renal insufficiency. J Clin Psychopharmacol 1993; 13:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/45\">",
"      Plenge P, Mellerup ET, Bolwig TG, et al. Lithium treatment: does the kidney prefer one daily dose instead of two? Acta Psychiatr Scand 1982; 66:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/46\">",
"      Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/47\">",
"      Broome JT, Solorzano CC. Lithium use and primary hyperparathyroidism. Endocr Pract 2011; 17 Suppl 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/48\">",
"      Saunders BD, Saunders EF, Gauger PG. Lithium therapy and hyperparathyroidism: an evidence-based assessment. World J Surg 2009; 33:2314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/49\">",
"      Khandwala HM, Van Uum S. Reversible hypercalcemia and hyperparathyroidism associated with lithium therapy: case report and review of literature. Endocr Pract 2006; 12:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/50\">",
"      Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psychiatr Pract 2005; 11:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/51\">",
"      Kloos AL, Dubin-Rhodin A, Sackett JC, et al. The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant. Curr Psychiatry Rep 2010; 12:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/52\">",
"      Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 2010; 44:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/53\">",
"      ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/54\">",
"      Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/55\">",
"      Cohen LS, Wang B, Nonacs R, et al. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am 2010; 33:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/56\">",
"      Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/3/43065/abstract/57\">",
"      Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011; 24:34.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15317 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5A1610FE52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43065=[""].join("\n");
var outline_f42_3_43065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H182696983\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H182696693\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H136818786\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385746629\">",
"      STRUCTURE AND FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H446684325\">",
"      ROLE IN TREATING BIPOLAR DISORDER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H446684335\">",
"      Reduced risk of suicide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H446684351\">",
"      Severely ill patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H446684761\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H182696749\">",
"      PRESCRIBING LITHIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182696765\">",
"      Lithium dose and serum concentrations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H446684831\">",
"      - Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182696772\">",
"      Lithium preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182696779\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182696786\">",
"      Lithium toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182696793\">",
"      Drug interactions with lithium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182696800\">",
"      Laboratory tests and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182696807\">",
"      Lithium side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H182696814\">",
"      - Acute side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H182696821\">",
"      - Long-term side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H68178733\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H68178740\">",
"      Thyroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H68178747\">",
"      Parathyroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H68179204\">",
"      Cardiac",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H182696969\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H182696983\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29273947\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/15317\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15317|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/53/3932\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/39/23164\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17756\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2874?source=related_link\">",
"      Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16330?source=related_link\">",
"      Geriatric bipolar disorder: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42453?source=related_link\">",
"      Lithium and the thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9225?source=related_link\">",
"      Lithium poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=related_link\">",
"      Lithium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/29/28117?source=related_link\">",
"      Lithium: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30361?source=related_link\">",
"      Pathogenesis and etiology of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/32999?source=related_link\">",
"      Renal toxicity of lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/50/17192?source=related_link\">",
"      Unipolar depression in adults: Treatment with lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38745?source=related_link\">",
"      Use of psychotropic medications in breastfeeding women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_3_43066="Erythema multiforme lip";
var content_f42_3_43066=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68153%7EDERM%2F62370%7EDERM%2F68682%7EEM%2F76141%7EEM%2F73805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68153%7EDERM%2F62370%7EDERM%2F68682%7EEM%2F76141%7EEM%2F73805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mucosal erosions and crusts on the lips of a patient with erythema multiforme.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple acrally distributed target lesions and mucosal erosions are present in this patient with erythema multiforme majus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stevens-Johnson syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions and crusts are present on the lips of this patient with Stevens-Johnson syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous findings of Stevens Johnson syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the vesicles and bulla that are characteristic of the cutaneous findings in Stevens Johnson syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mucosal changes in Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes similar to those observed in SJS/TEN can be observed also in erythema multiforme majus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43066=[""].join("\n");
var outline_f42_3_43066=null;
var title_f42_3_43067="Oral antimicrobial doses";
var content_f42_3_43067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral antimicrobials for pneumococcal pneumonia in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antimicrobial",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillin V",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Four times daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxicillin/clavulanate",
"       </td>",
"       <td>",
"        875/125 mg",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxicillin",
"       </td>",
"       <td>",
"        1 gram",
"       </td>",
"       <td>",
"        Three times daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Clarithromycin",
"       </td>",
"       <td>",
"        250 mg",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1000 mg (two 500 mg extended release tablets)",
"       </td>",
"       <td>",
"        Once&nbsp;daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Azithromycin",
"       </td>",
"       <td>",
"        500 mg on day one",
"       </td>",
"       <td>",
"        250 mg thereafter once daily for 4 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Once daily for three days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 grams",
"       </td>",
"       <td>",
"        As a single dose microsphere regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin",
"       </td>",
"       <td>",
"        333 mg",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43067=[""].join("\n");
var outline_f42_3_43067=null;
var title_f42_3_43068="Heparin nomogram for stroke";
var content_f42_3_43068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F53377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F53377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Heparin-adjusted nomogram for stroke",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"4\" rowspan=\"1\">",
"        Initial dosing for continuous intravenous heparin infusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Weight (kg)",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Initial infusion (U/hour)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &lt;50",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        50 to 59",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        60 to 69",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        700",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        70 to 79",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        80 to 89",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        900",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        90 to 99",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        100 to 109",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        1100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        110 to 119",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        1200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &gt;119",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        1400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"4\" rowspan=\"1\">",
"        Heparin adjustment based upon aPTT drawn six hours after initiation of therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        aPTT (seconds)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Stop infusion",
"       </td>",
"       <td class=\"subtitle2\">",
"        Rate change",
"       </td>",
"       <td class=\"subtitle2\">",
"        Repeat aPTT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;40",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Increase by 250 U/hour",
"       </td>",
"       <td>",
"        6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40 to 49",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Increase by 150 U/hour",
"       </td>",
"       <td>",
"        6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 to 59",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Increase by 100 U/hour",
"       </td>",
"       <td>",
"        6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60 to 90",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        Next morning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        91 to 100",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Decrease by 100 U/hour",
"       </td>",
"       <td>",
"        6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        101 to 120",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Decrease by 150 U/hour",
"       </td>",
"       <td>",
"        6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;120",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Decrease by 250 U/hour",
"       </td>",
"       <td>",
"        6 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    No bolus is administered in patients with acute stroke.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Toth C, Voll C. Validation of a weight-based nomogram for the use of intravenous heparin in transient ischemic attack or stroke. Stroke 2002; 33:670.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43068=[""].join("\n");
var outline_f42_3_43068=null;
var title_f42_3_43069="Antidepressant side eff PI";
var content_f42_3_43069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chance of side effects with certain antidepressant medicines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medicine name*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chance that it will make you sleepy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chance that it will make it hard to sleep or make you jittery",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chance that it will upset your stomach",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chance that it will cause sexual problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Selective serotonin reuptake inhibitors (SSRIs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Citalopram",
"        </p>",
"        <p>",
"         (Celexa&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Escitalopram",
"        </p>",
"        <p>",
"         (Lexapro&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Fluoxetine",
"        </p>",
"        <p>",
"         (Prozac&reg;, Prozac Weekly&reg;, Sarafem&reg;, Selfemra&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Fluvoxamine",
"        </p>",
"        <p>",
"         (only available as generic)",
"        </p>",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Fluvoxamine CR",
"        </p>",
"        <p>",
"         (Luvox&reg; CR)",
"        </p>",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Paroxetine",
"        </p>",
"        <p>",
"         (Paxil&reg;, Pexeva&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Paroxetine CR",
"        </p>",
"        <p>",
"         (Paxil CR&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Sertraline",
"        </p>",
"        <p>",
"         (Zoloft&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Dopamine-norepinephrine reuptake inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Bupropion",
"        </p>",
"        <p>",
"         (Wellbutrin&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Bupropion SR",
"        </p>",
"        <p>",
"         (Wellbutrin SR&reg;, Budeprion SR&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Bupropion XL",
"        </p>",
"        <p>",
"         (Wellbutrin XL&reg;, Budeprion XL&reg;, Aplenzin&trade;)",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Serotonin-norepinephrine reuptake inhibitors (SNRIs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Duloxetine",
"        </p>",
"        <p>",
"         (Cymbalta&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Venlafaxine",
"        </p>",
"        <p>",
"         (Effexor&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Venlafaxine XR",
"        </p>",
"        <p>",
"         (Effexor XR&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low/medium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Serotonin modulators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Nefazodone",
"        </p>",
"        <p>",
"         (only available as generic)",
"        </p>",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Trazodone",
"        </p>",
"        <p>",
"         (Oleptro&trade;)",
"        </p>",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Noradrenergic and specific serotonergic antidepressant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Mirtazapine",
"        </p>",
"        <p>",
"         (Remeron&reg;, Remeron SolTab&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * US brand names of medicines shown.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Antidepressant Medicines - A guide for adults with depression. US Department of Health &amp; Human Services. AHRQ publication number 07-EHC007-2A. 2007. Available at",
"     <a href=\"file://www.effectivehealthcare.ahrq.gov/ehc/products/7/10/AntidepressantsConsumerGuide.pdf\" target=\"_blank\">",
"      file://www.effectivehealthcare.ahrq.gov/ehc/products/7/10/AntidepressantsConsumerGuide.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43069=[""].join("\n");
var outline_f42_3_43069=null;
var title_f42_3_43070="Crohns fistulae UGI";
var content_f42_3_43070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ileocecal fistulae in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel follow through examination demonstrates nodular thickening of the terminal ileal mucosal folds in a patient with Crohn's disease (black arrow). Several fistulae extend from the terminal ileum to the adjacent cecum (white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43070=[""].join("\n");
var outline_f42_3_43070=null;
var title_f42_3_43071="Metacarpal shaft fracture with apex dorsal angulation";
var content_f42_3_43071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F79399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F79399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Metacarpal shaft fracture with apex dorsal angulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 191px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A metacarpal shaft fracture often develops an apex dorsal angulation due to the intrinsic muscle and the long flexors that cross volar to the axis of the metacarpophalangeal joint (MCPJ).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_3_43071=[""].join("\n");
var outline_f42_3_43071=null;
